Author: "Uccello G" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Uccello G"' showing total 103 results

Start Over Author "Uccello G"

103 results on '"Uccello G"'

1. P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN

Author: Del Fabro, V., primary, Schininà, G., additional, Sapuppo, G., additional, Uccello, G., additional, Gentile, M., additional, Palumbo, F., additional, Romano, A., additional, Di Raimondo, F., additional, and Conticello, C., additional
Published: 2023
Full Text: View/download PDF

2. Gender Difference in the Effects of COVID-19 Pandemic on Mechanical Reperfusion and 30-Day Mortality for STEMI: Results of the ISACS-STEMI COVID-19 Registry.

Author: Luca, G. De, Manzo-Silberman, S., Algowhary, M., Uguz, B., Oliveira, D.C., Ganyukov, V., Busljetik, O., Cercek, M., Okkels, L., Loh, P.H., Calmac, L., Ferrer, G.R.I., Quadros, A., Milewski, M., otto di Uccio, F. Sc, Birgelen, C. von, Versaci, F., Berg, J ., Casella, G., Wong Sung Lung, A., Kala, P., Díez Gil, J.L., Carrillo, X., Dirksen, M., Becerra, V., Lee, M.K., Juzar, D.A., Moura Joaquim, R. de, Paladino, R., Milicic, D., Davlouros, P., Bakraceski, N., Zilio, F., Donazzan, L., Kraaijeveld, A., Galasso, G., Arpad, L., Marinucci, L., Guiducci, V., Menichelli, M., Scoccia, A., Yamac, A.H., Ugur Mert, K., Flores Rios, X., Kovarnik, T., Kidawa, M., Moreu, J., Flavien, V., Fabris, E., Martínez-Luengas, I.L., Boccalatte, M., Ojeda, F.B., Arellano-Serrano, C., Caiazzo, G., Cirrincione, G., Kao, H.L., Forés, J.S., Vignali, L., Pereira, H., Ordoñez, S., Arat Özkan, A., Scheller, B., Lehtola, H., Teles, R., Mantis, C., Antti, Y., Brum Silveira, J.A., Zoni, C.R., Bessonov, I., Uccello, G., Kochiadakis, G., Alexopulos, D., Uribe, C.E., Kanakakis, J., Faurie, B., Gabrielli, G., Barrios, A.G., Bachini, J.P., Rocha, A., Tam, F.C., Rodriguez, A., Lukito, A.A., Saint-Joy, V., Pessah, G., Tuccillo, A., Ielasi, A., Cortese, G., Parodi, G., Bouraghda, M.A., Moura, M., Kedhi, E., Lamelas, P., Suryapranata, H., Nardin, M., Verdoia, M., Luca, G. De, Manzo-Silberman, S., Algowhary, M., Uguz, B., Oliveira, D.C., Ganyukov, V., Busljetik, O., Cercek, M., Okkels, L., Loh, P.H., Calmac, L., Ferrer, G.R.I., Quadros, A., Milewski, M., otto di Uccio, F. Sc, Birgelen, C. von, Versaci, F., Berg, J ., Casella, G., Wong Sung Lung, A., Kala, P., Díez Gil, J.L., Carrillo, X., Dirksen, M., Becerra, V., Lee, M.K., Juzar, D.A., Moura Joaquim, R. de, Paladino, R., Milicic, D., Davlouros, P., Bakraceski, N., Zilio, F., Donazzan, L., Kraaijeveld, A., Galasso, G., Arpad, L., Marinucci, L., Guiducci, V., Menichelli, M., Scoccia, A., Yamac, A.H., Ugur Mert, K., Flores Rios, X., Kovarnik, T., Kidawa, M., Moreu, J., Flavien, V., Fabris, E., Martínez-Luengas, I.L., Boccalatte, M., Ojeda, F.B., Arellano-Serrano, C., Caiazzo, G., Cirrincione, G., Kao, H.L., Forés, J.S., Vignali, L., Pereira, H., Ordoñez, S., Arat Özkan, A., Scheller, B., Lehtola, H., Teles, R., Mantis, C., Antti, Y., Brum Silveira, J.A., Zoni, C.R., Bessonov, I., Uccello, G., Kochiadakis, G., Alexopulos, D., Uribe, C.E., Kanakakis, J., Faurie, B., Gabrielli, G., Barrios, A.G., Bachini, J.P., Rocha, A., Tam, F.C., Rodriguez, A., Lukito, A.A., Saint-Joy, V., Pessah, G., Tuccillo, A., Ielasi, A., Cortese, G., Parodi, G., Bouraghda, M.A., Moura, M., Kedhi, E., Lamelas, P., Suryapranata, H., Nardin, M., and Verdoia, M.
Abstract: Item does not contain fulltext, BACKGROUND: Several reports have demonstrated the impact of the COVID-19 pandemic on the management and outcome of patients with ST-segment elevation myocardial infarction (STEMI). The aim of the current analysis is to investigate the potential gender difference in the effects of the COVID-19 pandemic on mechanical reperfusion and 30-day mortality for STEMI patients within the ISACS-STEMI COVID-19 Registry. METHODS: This retrospective multicenter registry was performed in high-volume primary percutaneous coronary intervention (PPCI) centers on four continents and included STEMI patients undergoing PPCIs in March-June 2019 and 2020. Patients were divided according to gender. The main outcomes were the incidence and timing of the PPCI, (ischemia time ≥ 12 h and door-to-balloon ≥ 30 min) and in-hospital or 30-day mortality. RESULTS: We included 16683 STEMI patients undergoing PPCIs in 109 centers. In 2020 during the pandemic, there was a significant reduction in PPCIs compared to 2019 (IRR 0.843 (95% CI: 0.825-0.861, p < 0.0001). We did not find a significant gender difference in the effects of the COVID-19 pandemic on the numbers of STEMI patients, which were similarly reduced from 2019 to 2020 in both groups, or in the mortality rates. Compared to prepandemia, 30-day mortality was significantly higher during the pandemic period among female (12.1% vs. 8.7%; adjusted HR [95% CI] = 1.66 [1.31-2.11], p < 0.001) but not male patients (5.8% vs. 6.7%; adjusted HR [95% CI] = 1.14 [0.96-1.34], p = 0.12). CONCLUSIONS: The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a 16% reduction in PPCI procedures similarly observed in both genders. Furthermore, we observed significantly increased in-hospital and 30-day mortality rates during the pandemic only among females. Trial registration number: NCT 04412655.
Published: 2023

3. Age-Related Effects of COVID-19 Pandemic on Mechanical Reperfusion and 30-Day Mortality for STEMI: Results of the ISACS-STEMI COVID-19 Registry.

Author: Luca, G. De, Algowhary, M., Uguz, B., Oliveira, D.C., Ganyukov, V., Busljetik, O., Cercek, M., Jensen, L.O., Loh, P.H., Calmac, L., Ferrer, G.R.I., Quadros, A., Milewski, M., Scotto D'Uccio, F., Birgelen, C. von, Versaci, F., Berg, J ., Casella, G., Wong Sung Lung, A., Kala, P., Díez Gil, J.L., Carrillo, X., Dirksen, M., Becerra Munoz, V., Lee, M.K., Juzar, D.A., Moura Joaquim, R. de, Paladino, R., Milicic, D., Davlouros, P., Bakraceski, N., Zilio, F., Donazzan, L., Kraaijeveld, A., Galasso, G., Arpad, L., Marinucci, L., Guiducci, V., Menichelli, M., Scoccia, A., Yamac, A.H., Ugur Mert, K., Flores Rios, X., Kovarnik, T., Kidawa, M., Moreu, J., Flavien, V., Fabris, E., Martínez-Luengas, I.L., Boccalatte, M., Bosa Ojeda, F., Arellano-Serrano, C., Caiazzo, G., Cirrincione, G., Kao, H.L., Sanchis Forés, J., Vignali, L., Pereira, H., Manzo-Silberman, S., Ordoñez, S., Arat Özkan, A., Scheller, B., Lehitola, H., Teles, R., Mantis, C., Antti, Y., Brum Silveira, J.A., Zoni, C.R., Bessonov, I., Uccello, G., Kochiadakis, G., Alexopulos, D., Uribe, C.E., Kanakakis, J., Faurie, B., Gabrielli, G., Gutierrez Barrios, A., Bachini, J.P., Rocha, Alex, Tam, F.C., Rodriguez, A., Lukito, A.A., Saint-Joy, V., Pessah, G., Tuccillo, A., Ielasi, A., Cortese, G., Parodi, G., Burgadha, M.A., Kedhi, E., Lamelas, P., Suryapranata, H., Nardin, M., Verdoia, M., Luca, G. De, Algowhary, M., Uguz, B., Oliveira, D.C., Ganyukov, V., Busljetik, O., Cercek, M., Jensen, L.O., Loh, P.H., Calmac, L., Ferrer, G.R.I., Quadros, A., Milewski, M., Scotto D'Uccio, F., Birgelen, C. von, Versaci, F., Berg, J ., Casella, G., Wong Sung Lung, A., Kala, P., Díez Gil, J.L., Carrillo, X., Dirksen, M., Becerra Munoz, V., Lee, M.K., Juzar, D.A., Moura Joaquim, R. de, Paladino, R., Milicic, D., Davlouros, P., Bakraceski, N., Zilio, F., Donazzan, L., Kraaijeveld, A., Galasso, G., Arpad, L., Marinucci, L., Guiducci, V., Menichelli, M., Scoccia, A., Yamac, A.H., Ugur Mert, K., Flores Rios, X., Kovarnik, T., Kidawa, M., Moreu, J., Flavien, V., Fabris, E., Martínez-Luengas, I.L., Boccalatte, M., Bosa Ojeda, F., Arellano-Serrano, C., Caiazzo, G., Cirrincione, G., Kao, H.L., Sanchis Forés, J., Vignali, L., Pereira, H., Manzo-Silberman, S., Ordoñez, S., Arat Özkan, A., Scheller, B., Lehitola, H., Teles, R., Mantis, C., Antti, Y., Brum Silveira, J.A., Zoni, C.R., Bessonov, I., Uccello, G., Kochiadakis, G., Alexopulos, D., Uribe, C.E., Kanakakis, J., Faurie, B., Gabrielli, G., Gutierrez Barrios, A., Bachini, J.P., Rocha, Alex, Tam, F.C., Rodriguez, A., Lukito, A.A., Saint-Joy, V., Pessah, G., Tuccillo, A., Ielasi, A., Cortese, G., Parodi, G., Burgadha, M.A., Kedhi, E., Lamelas, P., Suryapranata, H., Nardin, M., and Verdoia, M.
Abstract: Contains fulltext : 291566.pdf (Publisher’s version ) (Open Access), BACKGROUND: The constraints in the management of patients with ST-segment elevation myocardial infarction (STEMI) during the COVID-19 pandemic have been suggested to have severely impacted mortality levels. The aim of the current analysis is to evaluate the age-related effects of the COVID-19 pandemic on mechanical reperfusion and 30-day mortality for STEMI within the registry ISACS-STEMI COVID-19. METHODS: This retrospective multicenter registry was performed in high-volume PPCI centers on four continents and included STEMI patients undergoing PPCI in March-June 2019 and 2020. Patients were divided according to age (< or ≥75 years). The main outcomes were the incidence and timing of PPCI, (ischemia time longer than 12 h and door-to-balloon longer than 30 min), and in-hospital or 30-day mortality. RESULTS: We included 16,683 patients undergoing PPCI in 109 centers. In 2020, during the pandemic, there was a significant reduction in PPCI as compared to 2019 (IRR 0.843 (95%-CI: 0.825-0.861, p < 0.0001). We found a significant age-related reduction (7%, p = 0.015), with a larger effect on elderly than on younger patients. Furthermore, we observed significantly higher 30-day mortality during the pandemic period, especially among the elderly (13.6% vs. 17.9%, adjusted HR (95% CI) = 1.55 [1.24-1.93], p < 0.001) as compared to younger patients (4.8% vs. 5.7%; adjusted HR (95% CI) = 1.25 [1.05-1.49], p = 0.013), as a potential consequence of the significantly longer ischemia time observed during the pandemic. CONCLUSIONS: The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a 16% reduction in PPCI procedures, with a larger reduction and a longer delay to treatment among elderly patients, which may have contributed to increase in-hospital and 30-day mortality during the pandemic.
Published: 2023

4. PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS

Author: Bruzzese, A., primary, Derudas, D., additional, Galli, M., additional, Martino, E. A., additional, Rocco, S., additional, Conticello, C., additional, Califano, C., additional, Giuliani, N., additional, Mangicavalli, S., additional, Farina, G., additional, Lombardo, A., additional, Brunori, M., additional, Rossi, E., additional, Antonioli, E., additional, Ria, R., additional, Zambello, R., additional, Di Renzo, N., additional, Mele, G., additional, Marcacci, G., additional, Pietrantuono, G., additional, Palumbo, G., additional, Cascavilla, N., additional, Cerchione, C., additional, Belotti, A., additional, Criscuolo, C., additional, Uccello, G., additional, Curci, P., additional, Vigna, E., additional, Mendicino, F., additional, Iaccino, E., additional, Mimmi, S., additional, Botta, C., additional, Vincelli, D., additional, Sgherza, N., additional, Bonalumi, A., additional, Cupelli, L., additional, Stocchi, R., additional, Martino, M., additional, Ballanti, S., additional, Gangemi, D., additional, Gagliardi, A., additional, Gamberi, B., additional, Pompa, A., additional, Tripepi, G., additional, Frigeri, F., additional, Consoli, U., additional, Bringhen, S., additional, Zamagni, E., additional, Patriarca, F., additional, De Stefano, V., additional, Di Raimondo, F., additional, Palmieri, S., additional, Petrucci, M. T., additional, Offidani, M., additional, Musto, P., additional, Boccadoro, M., additional, Cavo, M., additional, Neri, A., additional, Morabito, F., additional, and Gentile, M., additional
Published: 2022
Full Text: View/download PDF

5. Circulating miRNA markers show promise as new prognosticators for multiple myeloma

Author: Rocci, A, Hofmeister, C C, Geyer, S, Stiff, A, Gambella, M, Cascione, L, Guan, J, Benson, D M, Efebera, Y A, Talabere, T, Dirisala, V, Smith, E M, Omedè, P, Isaia, G, De Luca, L, Rossi, D, Gentili, S, Uccello, G, Consiglio, J, Ria, R, Benevolo, G, Bringhen, S, Callea, V, Weiss, B, Ferro, A, Magarotto, V, Alder, H, Byrd, J C, Boccadoro, M, Marcucci, G, Palumbo, A, and Pichiorri, F
Published: 2014
Full Text: View/download PDF

6. Benefits assessment of liposomal iron (Sideral® Forte) administration to hematologic patients in follow-up after chemotherapy

Author: Petrungaro, A, Mineo, G, Cingari, R, Crispi, F, Uccello, G, Santonocito, A M, and Longo, G
Published: 2015

7. Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

Author: Romano, A., Chiarenza, A., Consoli, U., Conticello, C., Forte, S., Uccello, G., Vetro, C., Cavalli, M., Coppolino, F., Palumbo, G. A., and Di Raimondo, F.
Published: 2013
Full Text: View/download PDF

8. 95 A rare case of Lactobacillus Plantarum prosthetic valve endocarditis

Author: Tavernese, A, primary, Caldara, F, additional, Muscoli, S, additional, Stelitano, M, additional, Uccello, G, additional, Mauceri, A, additional, Mollace, R, additional, Sordillo, P, additional, Andreoni, M, additional, Romeo, F, additional, and Cammalleri, V, additional
Published: 2020
Full Text: View/download PDF

9. P748 Three-year echocardiographic outcomes in MitraClip patients with chronic kidney disease

Author: Tavernese, A, primary, Cammalleri, V, additional, Sanseviero, A, additional, De Vico, P, additional, Muscoli, S, additional, Cuzzola, B, additional, Uccello, G, additional, Mauceri, A, additional, Stelitano, M, additional, Mollace, R, additional, Macrini, M, additional, and Romeo, F, additional
Published: 2020
Full Text: View/download PDF

10. P1362 Echocardiographic findings and BNP levels in patients with valve-in-valve implantation in small failed mitroflow aortic prosthesis

Author: Muscoli, S, primary, Cammalleri, V, additional, Cosma, J, additional, Zuccaro, M, additional, Macrini, M, additional, Mollace, R, additional, Tavernese, A, additional, Mauceri, A, additional, Stelitano, M, additional, Uccello, G, additional, De Vico, P, additional, and Romeo, F, additional
Published: 2020
Full Text: View/download PDF

11. P1296 Effects of contact-to-balloon time on variations of the left ventricle global and regional function during hospitalization of STEMI patients: an echocardiographic study

Author: Cammalleri, V, primary, Stelitano, M, additional, Muscoli, S, additional, Marsili, G, additional, Manzon, W, additional, Tavernese, A, additional, Monaco, C, additional, Zanin, F, additional, Uccello, G, additional, Bonanni, M, additional, Mauceri, A, additional, Macrini, M, additional, Di Landro, A, additional, Mollace, R, additional, and Romeo, F, additional
Published: 2020
Full Text: View/download PDF

12. P299 Acute effects of Levosimendan on myocardial function in patients with severe mitral regurgitation and left ventricular dysfunction undergoing MitraClip repair

Author: Cammalleri, V, primary, Tavernese, A, additional, De Vico, P, additional, Macrini, M, additional, Gismondi, A, additional, Muscoli, S, additional, Mauceri, A, additional, Stelitano, M, additional, Uccello, G, additional, Mollace, R, additional, Marino, M M, additional, and Romeo, F, additional
Published: 2020
Full Text: View/download PDF

13. P581Hypertrophic cardiomyopathy, myocardial bridging and tako-tsubo syndrome: on the trail of the culprit

Author: Uccello, G, primary, Cammalleri, V, additional, Stelitano, M, additional, Tavernese, A, additional, and Romeo, F, additional
Published: 2019
Full Text: View/download PDF

14. Multidisciplinary treatment of primary orbital rhabdomyosarcoma: a single-institution experience

Author: Fiorillo, Amedeo, Migliorati, R., Grimaldi, M., Vassallo, P., Canale, G., Tranfa, F., Uccello, G., Fiore, M., Muto, P., Menna, G., Parasole, R., and Bonavolonta, G.
Subjects: Eye cancer -- Care and treatment, Cancer in children -- Care and treatment, Chemotherapy, Combination -- Evaluation, Rhabdomyosarcoma -- Care and treatment, Health
Abstract: Overall, rhabdomyosarcomas are not common, but they are among the most frequent tumors of muscle tissue. Among children, rhabdomyosarcomas account for four to eight percent of cancers. While many rhabdomyosarcomas have a poor prognosis, patients enjoy a far better prognosis if the disease is limited to the eye socket, or orbit. Published studies indicate a two-year survival rate of about 90 percent. In a retrospective evaluation of the treatment of 12 children, the authors indicate that the current treatment method, which combines radiotherapy with chemotherapy, can be completely effective when properly applied. Ten of the 12 patients were immediately treated with radiation and combined chemotherapy upon diagnosis, and two patients were treated with radiotherapy upon recurrence. The authors view the treatment of these two patients as corrective, in that the initial treatment was not properly applied. All 12 patients are alive without evidence of disease at follow-up periods ranging from 7 to 123 months. Eleven of the 12 patients received a radiation dose of 6,000 cGy (a Gy, or Gary, is one Joule of energy absorbed per kilogram of tissue). This level of radiation, when administered to the eye, is believed to cause cataracts. In the present series of patients, cataract formation was observed in only one patient, and lens opacities occurred in another two. An additional eight patients retain good visual acuity; the remaining patient had almost total lack of vision prior to treatment. The excellent preservation of vision is attributed to immediate treatment with radiotherapy. The ability of the eye to recover from radiation exposure may be compromised if radiotherapy is delayed until after chemotherapy. Therefore, treatment should not be delayed once a diagnosis of rhabdomyosarcoma of the orbit is confirmed. The authors suggest that the currently available treatment methods are already optimal and require only proper administration. (Consumer Summary produced by Reliance Medical Information, Inc.)
Published: 1991

15. Rilevazione statistica della diffusione e della conoscenza di sostanze dopanti, integratori e dell' Exercise Addiction

Author: VENTURELLA, Fabio, Uccello, G, Aiello, F, Sanfilippo, C, Passavanti, G, Mandalà, M., Venturella, F, Uccello, G, Aiello, F, Sanfilippo, C, Passavanti, G, and Mandalà, M
Subjects: Settore BIO/14 - Farmacologia, Doping amatoriale, abuso integratori , exercise addiction
Abstract: I benefici derivanti dalla pratica dell'esercizio fisico sono stati ampiamente documentati. Tuttavia, l’eccessivo ricorso alla attività fisica può condurre alla messa in atto di pattern compulsivi di allenamento che possono evolversi in una vera e propria patologia: l' exercise addiction. Studi recenti suggeriscono l'espansione di due fenomeni: il doping amatoriale e l'abuso di integratori per lo sport. Sono stati somministrati 686 test. I partecipanti allo studio sono stati scelti tra studenti di scuola media superiore, studenti universitari e frequentatori di ambienti sportivi. Il 42,5% degli intervistati dichiara di assumere sostanze per migliorare le prestazioni sportive e quindi di doparsi. Il 30,23% assume integratori. Una percentuale compresa tra il 35 e l'88,35 % dichiara di non conoscere le sostanze proposte.Il 15,8% dei rispondenti è a “rischio” di exercise addiction, il 71,7% è classificato come “sintomatico”. E' stata infine indagata quale possibile correlazione potesse esserci tra le variabili in esame. La statistica test X2 evidenzia che non vi è alcuna associazione , in altre parole non sembra esserci relazione tra il rischio di dipendenza dall' esercizio fisico e l'assunzione di sostanze. L'analisi dei dati raccolti suggerisce invece che vi sia un'espansione del fenomeno del doping in ambiente amatoriale e che vi sia una scriteriata e incongrua assunzione di integratori per lo sport. La presente ricerca suggerisce che occorre compiere interventi immediati sia a livello di informazione che di prevenzione , in cui al farmacista sia affidato un ruolo di primo piano.
Published: 2014

16. Centri di Patologia Orbitaria: distribuzione sul territorio e prospettive

Author: Uccello G., Tanfa F., Bonavolontà G., STRIANESE, DIEGO, Uccello, G., Strianese, Diego, Tanfa, F., and Bonavolontà, G.
Subjects: orbital centre, orbital tumors
Abstract: Obiettivo di questo lavoro è stato quello di valutare l'incidenza dei casi affetti da Patologia Orbitaria e l'eventuale variazione negli ultimi anni, e stabilire se questi dati giustificano l'esistenza di un centro specializzato per la diagnosi, la cura e lo studio di queste malattie. Scopo dello studio sarà anche quello di riportare il numero di morti causati dai tumori orbitari e il numero di pazienti con perdita della funzione visiva causate da lesioni orbitarie. Studio retrospettivo basato su una serie di casi affetti da malattie dell'orbita registrati in un singolo centro in un periodo di 26 anni. In questo periodo 4000 casi sono stati osservati provenienti da una area geografica di circa 20000000 abitanti (0,02 incidenza approssimativa). Alcuni tipi di tumori sono aumentati negli ultimi anni, in particolare i linfomi, la cui frequenza si è accresciuta circa il 50%. La mortalità generica causata da una neoformazione orbitaria è risultata essere del 9% e la compromissione della funzione visiva è stata del 7%. Il numero di pazienti esaminato è sufficiente per concludere che la Patologia Orbitaria ha un importante impatto sociale sia per quel che concerne il rischio di vita, sia per il rischio di compromissione della funzione visiva. Per migliorare la conoscenza e il trattamento delle malattie orbitarie è utile la presenza di un centro specializzato ogni 20 milioni di abitanti circa.
Published: 2004

17. Chemistry change with size: nucleation and growth of metal atoms to particles of tailored dimensions

Author: Vitulli G., Evangelisti C., Raffa P., Uccello G., Barretta G., Martra G., Coluccia S., and Salvadori P.
Published: 2006

18. Free levator complex recession in Graves' ophthalmopathy. Our experience

Author: Uccello G., Vassallo P., Bonavolonta, STRIANESE, DIEGO, Uccello, G., Vassallo, P., Strianese, Diego, and Bonavolonta
Subjects: surgery, eyelid retraction, graves disease
Abstract: The use of scleral graft has been suggested in patients with upper lid retraction due to thyroid ophthalmopathy to correct severe cases and to avoid unpredictable results. But this technique is more complicated than others and more time-consuming. The authors have used a free recession technique to deal with the functional and cosmetic problems of these patients. The results of a group of 60 patients (98 eyes) with Graves' ophthalmopathy who were referred to their institute over the last ten years and underwent eyelid surgery were evaluated. Free recession surgery achieved good results in 75% of all cases after one procedure. In spite of careful preoperative evaluation the remaining patients needed additional surgery to achieve a good final result. However, in some cases the outcome of the surgery in upper lid retraction remains unpredictable.
Published: 1994

19. Multidisciplinary treatment of primary orbital rhabdomiosarcoma. A single- Institution experience

Author: FIORILLO A, MIGLIORATI R, GRIMALDI M, VASSALLO P, CANALE G, TRANFA F, UCCELLO G, FIORE M, MUTO P, MENNA G, PARASOLE R, BONAVOLONTA', GIULIO, Fiorillo, A, Migliorati, R, Grimaldi, M, Vassallo, P, Canale, G, Tranfa, F, Uccello, G, Fiore, M, Muto, P, Menna, G, Parasole, R, and Bonavolonta', Giulio
Published: 1991

20. miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients

Author: Andrew Stiff, Alberto Rocci, Craig C. Hofmeister, Paola Omedè, Susan Geyer, Sara Bringhen, Luciano Cascione, Anissa Bingman, Manuela Gambella, Federica Cavallo, Luciana De Luca, Jingwen Guan, Alessandra Larocca, Jacqueline Corry, Francesca Gay, Yvonne A Efebera, Uccello G, Don M. Benson, Tiffany Talabere, Kevin Murnan, Magarotto Valeria, Mario Boccadoro, Carlo M. Croce, Antonio Palumbo, and Flavia Pichiorri
Subjects: Pathology, medicine.medical_specialty, Creatinine, biology, Beta-2 microglobulin, Myeloma protein, Immunology, C-reactive protein, Cell Biology, Hematology, medicine.disease, Biochemistry, Pathogenesis, chemistry.chemical_compound, medicine.anatomical_structure, chemistry, medicine, biology.protein, Bone marrow, Precordial catch syndrome, Multiple myeloma
Abstract: Abstract 2921 Background: Multiple myeloma (MM) is a clonal B-cell malignancy characterized by the aberrant expansion of clonal plasma cells (PCs) within the bone marrow. Malignant PCs produce intact or partial monoclonal immunoglobulin (M protein) and cause organ damage. More than 20,000 new cases of multiple myeloma (MM) are diagnosed every year in the US with approximately 10,700 deaths occurring. The pathogenesis of MM is still largely unclear, but several reports suggest that interaction of tumor cells with the bone marrow microenvironment and microRNAs (miRNAs) deregulation may play a role in the etiology and progression of MM. miRNAs are small non-coding RNAs capable of regulating protein expression by binding to mRNA, and have been implicated in the development of MM. First identified inside cells, miRNAs can also be detected in body fluids, including serum and plasma, and may be a valid biomarker. Few studies have investigated the agreement between circulating miRNAs and intracellular myeloma PC miRNAs at diagnosis. Methods: Using Nano-String nCounter technology we first performed a screening analysis on serum samples obtained from MM patients and healthy controls. We identified a candidate set of miRNAs differentially expressed in the serum of MM patients. The levels of these miRNA markers were validated by RT-PCR in both serum and bone marrow PCs from the same cohort. Agreement of the quantitative miRNA marker levels between sample types was evaluated using intraclass correlation coefficients (ICC) (both for normalized and log2 measures). Results: Thirty-nine MM patients (21 male, 18 female) with a median age of 72 years (range: 65 – 83) were included in the analysis. Most were ISS stage I or II (59% vs. 41% ISS stage III) and 39% were high risk according to FISH abnormalities – 21% of patients carried del17p, 24% t(4;14) and 5% t(14;16). Medians and ranges for lab markers were as follows: hemoglobin 10.0 g/dl (7.2 to 15.1), beta2-microglobulin 5.18 ug/ml (1.38 – 12.1), creatinine 0.94 mg/dl (0.65 – 2.49), CRP = 1.6 mg/dl (0.02 – 116.0). Nine age-matched healthy controls were also used for the analysis. After the screening analysis, the following miRNAs were differentially expressed between healthy subjects and MM patients in serum samples: miR-92a, miR-451, miR-19b, miR-21, miR-16, miR-25, miR-30a, and miR-126. There was no significant agreement or correlation between serum and myeloma cell samples using either untransformed as well as log2measures (all p>0.40) (Table 1). Conclusion: Our preliminary results suggest a difference between circulating miRNAs in myeloma patients from controls. This indicates that future studies are needed to better define the role of miRNAs in the peripheral blood as a prognostic and even diagnostic biomarker in myeloma. From our preliminary data it also appears that circulating miRNAs are not simply secreted into the peripheral blood by myeloma PCs as it seems that circulating miRNAs do not reflect those of myeloma PCs. Differential expression could be determined by other cells that can release and or modify their miRNA expression in response to MM. Ongoing studies are examining the origin and function of miRNAs in the peripheral blood. Disclosures: No relevant conflicts of interest to declare.
Published: 2012

21. CT scan in the differential diagnosis of thickened optic nerve.

Author: Uccello, G., Fedriga, P., Tranfa, F., Vassallo, P., and Bonavolonta, G.
Published: 1986
Full Text: View/download PDF

22. Our experience with intralesional corticosteroid injection therapy for infantile adnexal hemangiomao.

Author: Bonavolont, G., Vassallo, P., Uccello, G., and Tranfa, F.
Published: 1985
Full Text: View/download PDF

23. P581 Hypertrophic cardiomyopathy, myocardial bridging and tako-tsubo syndrome: on the trail of the culprit.

Author: Uccello, G, Cammalleri, V, Stelitano, M, Tavernese, A, and Romeo, F
Subjects: CONFERENCES & conventions, CARDIAC hypertrophy, TAKOTSUBO cardiomyopathy
Published: 2019
Full Text: View/download PDF

24. ADVANCED AGE, ORGAN DAMAGE AND ADVERSE EVENTS NEGATIVELY AFFECT SURVIVAL OF MYELOMA PATIENTS RECEIVING NOVEL AGENTS: A META-ANALYSIS OF 1435 INDIVIDUAL PATIENT DATA FROM 4 RANDOMIZED CLINICAL TRIALS

Author: Larocca, A., Bringhen, S., Mateos, M. V., Genuardi, M., Rossi, D., Zweegman, S., Oliva, S., Oriol, A., Palladino, C., Wijermans, P., Liberati, A. M., Juan José Lahuerta, Uccello, G., Schaafsma, M., Falcone, A., Teruel, A., Ria, R., Holt, B., Siniscalchi, A., San Miguel, J., Caraffa, P., Allegra, A., Zambello, R., Cangialosi, C., Ciccone, G., Aschero, S., Sonneveld, P., Boccadoro, M., Palumbo, A., CCA - Treatment and quality of life, CCA - Imaging and biomarkers, CCA - Cancer biology and immunology, and Hematology
Abstract: Background Multiple myeloma (MM) is the most relevant hematologic tumor in the elderly population. Median age at diagnosis is 70 years; 37% of patients are older than 75 years and 30% of patients present at diagnosis at least one co-morbid condition. The introduction of novel agents, bortezomib, thalidomide and lenalidomide, have changed the treatment paradigm of elderly MM, but side effects are frequent and full-drug doses less tolerated. Up to 90% of at least one serious adverse event (AE), with a subsequent 40% of drug discontinuation has been reported. Aims. A retrospective analysis evaluating 1435 individual patient data from 4 European phase III trials was conducted. We analyzed the impact of age, organ damage, treatment-related AEs and drug discontinuation as predictors of outcome. Methods. Patients with newly diagnosed MM, not eligible for autologous transplantation due to age (≥65 years) or co-morbidities, received melphalan-prednisone (MP), MP-thalidomide (MPT), MP-bortezomib (VMP), bortezomib-thalidomide-prednisone (VTP) or VMP-thalidomide (VMPT). Patients enrolled in the GISMM-2001 MP vs. MPT (331 patients), HOVON 49 MP vs. MPT (333 patients), GEM05MAS VMP vs. VTP (260 patients) and GIMEMA MM0305 VMP vs. VMPT (511 patients) trials were included in this meta-analysis. Trials were registered at ClinicalTrials.gov or controlled-trials.com. Results. Of the 1435 patients analysed, 332 did not receive novel agents (MP), 332 received thalidomide (MPT), 387 bortezomib (VMP), 384 thalidomide and bortezomib (VTP/ VMPT). Patients ≥75 years were 36%, equally distributed in the 4 groups. The proportion of patients with ISS III was lower in the MP group; renal failure was higher in the MP and MPT groups, due to less stringent selection of these protocols. The incidence of any grade 3-4 non-hematologic AEs was 29%, higher in MPT (43%) compared with VMP (24%) or VTP/VMPT (32%) groups. The most frequent were infections (10%), peripheral neuropathy (8%), cardiac (6%) and gastro-intestinal complications (5%). Drug discontinuation for toxicity was 27%, higher in MPT (35%) compared with VMP (16%) or VTP/VMPT (29%) groups.After a median follow-up of 33 months (95% Confidence Interval [CI] 10-56 months), 513/1435 patients (36%) died, the median overall survival was 50 months (95% CI 46-60 months). The causes of death were disease progression (76%) and toxic effects (24%), mainly infections, cardiac complications, second primary malignancies, and venous thromboembolism. The risk of death was increased in patients ≥75 years (Hazard Ratio [HR] 1.44, 95% CI 1.20-1.72, P

25. MICROENVIRONMENT REGULATION OF PROGRAMMED DEATH-1 (PD1) RECEPTOR AND ITS LIGANDS PDL1 AND PDL2 IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Author: Bossio, S., Tripodo, C., Recchia, A. G., Stefano, L., Caruso, N., Palummo, A., Storino, F., Gentile, M., Vigna, E., Petrungaro, A. M., Vincelli, I. D., Daniela FENOGLIO, Filaci, G., Fais, F., Uccello, G., Gulino, A., Vallone, R., Manzoni, M., Neri, A., Cutrona, G., Tassone, P., Ferrarini, M., and Morabito, F.

26. LENALIDOMIDE (LEN) DRIVES PROGRAMMED DEATH-1 (PD1) PATHWAY UPREGULATION IN A TUMOR MICROENVIRONMENT (TME) MODEL OF ACTIVATED LOW-GRADE LYMPHOMA CELLS

Author: Bossio, S., Claudio Tripodo, Recchia, A. G., Stefano, L., Caruso, N., Palummo, A., Storino, F., Gentile, M., Vigna, E., Petrungaro, A. M., Fenoglio, D., Filaci, G., Fais, F., Uccello, G., Gulino, A., Stellitano, C., Manzoni, M., Neri, A., Cutrona, G., Tassone, P., Ferrarini, M., and Morabito, F.

27. IN VITRO MODULATION OF PROGRAMMED DEATH-1 (PD1) RECEPTOR AND ITS LIGANDS PDL1 AND PDL2 PROTEINS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) BY THE TUMOR MICROENVIRONMENT (TME)

Author: Bossio, S., Recchia, A. G., Stefano, L., Caruso, N., Palummo, A., Iaquinta, G., Storino, F., Gentile, M., Vigna, E., Fenoglio, D., Filaci, G., Uccello, G., Mazoni, M., Neri, A., Giovanna Cutrona, Tripodo, C., Tassone, P. F., and Morabito, F.

28. ELOTUZUMAB, LENALIDOMIDE, AND DEXAMETHASONE (ELORD) AS SALVAGE THERAPY FOR PATIENTS WITH MULTIPLE MYELOMA: ITALIAN, MULTICENTER, RETROSPECTIVE CLINICAL EXPERIENCE WITH 300 CASES OUTSIDE OF CONTROLLED CLINICAL TRIALS

Author: Gentile, M., Specchia, G., Derudas, D., Galli, M., Rocco, S., Conticello, C., Califano, C., Giuliani, N., Mangiacavalli, S., Attingenti, E., Lombardo, A., Brunori, M., Rossi, E., Antonioli, E., Ria, R., Zambello, R., Di Renzo, N., Mele, G., Marcacci, G., Musto, P., Capalbo, S., Cascavilla, N., Claudio Cerchione, Belotti, A., Criscuolo, C., Uccello, G., Curci, P., Vigna, E., Vincelli, D., Bonalumi, A., Siniscalchi, A., Stocchi, R., Martino, M., Ballanti, S., Gangemi, D., Gagliardi, A., Gamberi, B., Pompa, A., Recchia, A. G., Tripepi, G., Frigeri, F., Consoli, U., Bringhen, S., Zamagni, E., Patriarca, F., Stefano, V., Di Raimondo, F., Ferrara, F., Morabito, F., Petrucci, M. T., and Offidani, M.

29. Gender Difference in the Effects of COVID-19 Pandemic on Mechanical Reperfusion and 30-Day Mortality for STEMI: Results of the ISACS-STEMI COVID-19 Registry

Author: Giuseppe De Luca, Stephane Manzo-Silberman, Magdy Algowhary, Berat Uguz, Dinaldo C. Oliveira, Vladimir Ganyukov, Oliver Busljetik, Miha Cercek, Lisette Okkels, Poay Huan Loh, Lucian Calmac, Gerard Roura i Ferrer, Alexandre Quadros, Marek Milewski, Fortunato Scotto di Uccio, Clemens von Birgelen, Francesco Versaci, Jurrien Ten Berg, Gianni Casella, Aaron Wong Sung Lung, Petr Kala, José Luis Díez Gil, Xavier Carrillo, Maurits Dirksen, Victor Becerra, Michael Kang-yin Lee, Dafsah Arifa Juzar, Rodrigo de Moura Joaquim, Roberto Paladino, Davor Milicic, Periklis Davlouros, Nikola Bakraceski, Filippo Zilio, Luca Donazzan, Adriaan Kraaijeveld, Gennaro Galasso, Lux Arpad, Lucia Marinucci, Vincenzo Guiducci, Maurizio Menichelli, Alessandra Scoccia, Aylin Hatice Yamac, Kadir Ugur Mert, Xacobe Flores Rios, Tomas Kovarnik, Michal Kidawa, Josè Moreu, Vincent Flavien, Enrico Fabris, Iñigo Lozano Martínez-Luengas, Marco Boccalatte, Francisco Bosa Ojeda, Carlos Arellano-Serrano, Gianluca Caiazzo, Giuseppe Cirrincione, Hsien-Li Kao, Juan Sanchis Forés, Luigi Vignali, Helder Pereira, Santiago Ordoñez, Alev Arat Özkan, Bruno Scheller, Heidi Lehtola, Rui Teles, Christos Mantis, Ylitalo Antti, João António Brum Silveira, Cesar Rodrigo Zoni, Ivan Bessonov, Giuseppe Uccello, George Kochiadakis, Dimitrios Alexopulos, Carlos E. Uribe, John Kanakakis, Benjamin Faurie, Gabriele Gabrielli, Alejandro Gutierrez Barrios, Juan Pablo Bachini, Alex Rocha, Frankie C. C. Tam, Alfredo Rodriguez, Antonia Anna Lukito, Veauthyelau Saint-Joy, Gustavo Pessah, Andrea Tuccillo, Alfonso Ielasi, Giuliana Cortese, Guido Parodi, Mohamed Abed Bouraghda, Marcia Moura, Elvin Kedhi, Pablo Lamelas, Harry Suryapranata, Matteo Nardin, Monica Verdoia, MUMC+: MA Med Staf Spec Cardiologie (9), RS: Carim - H01 Clinical atrial fibrillation, Cardiologie, De Luca, G., Manzo-Silberman, S., Algowhary, M., Uguz, B., Oliveira, D. C., Ganyukov, V., Busljetik, O., Cercek, M., Okkels, L., Loh, P. H., Calmac, L., Ferrer, G. R. I., Quadros, A., Milewski, M., Scotto di Uccio, F., von Birgelen, C., Versaci, F., Ten Berg, J., Casella, G., Wong Sung Lung, A., Kala, P., Diez Gil, J. L., Carrillo, X., Dirksen, M., Becerra, V., Lee, M. K. -Y., Juzar, D. A., de Moura Joaquim, R., Paladino, R., Milicic, D., Davlouros, P., Bakraceski, N., Zilio, F., Donazzan, L., Kraaijeveld, A., Galasso, G., Arpad, L., Marinucci, L., Guiducci, V., Menichelli, M., Scoccia, A., Yamac, A. H., Ugur Mert, K., Flores Rios, X., Kovarnik, T., Kidawa, M., Moreu, J., Flavien, V., Fabris, E., Martinez-Luengas, I. L., Boccalatte, M., Ojeda, F. B., Arellano-Serrano, C., Caiazzo, G., Cirrincione, G., Kao, H. -L., Fores, J. S., Vignali, L., Pereira, H., Ordonez, S., Arat Ozkan, A., Scheller, B., Lehtola, H., Teles, R., Mantis, C., Antti, Y., Brum Silveira, J. A., Zoni, C. R., Bessonov, I., Uccello, G., Kochiadakis, G., Alexopulos, D., Uribe, C. E., Kanakakis, J., Faurie, B., Gabrielli, G., Barrios, A. G., Bachini, J. P., Rocha, A., Tam, F. C. C., Rodriguez, A., Lukito, A. A., Saint-Joy, V., Pessah, G., Tuccillo, A., Ielasi, A., Cortese, G., Parodi, G., Bouraghda, M. A., Moura, M., Kedhi, E., Lamelas, P., Suryapranata, H., Nardin, M., and Verdoia, M.
Subjects: IMPACT, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], percutaneous coronary intervention, PRIMARY ANGIOPLASTY, COVID-19, General Medicine, ADMISSION, ST-segment elevation myocardial infarction, INSIGHTS, WUHAN, All institutes and research themes of the Radboud University Medical Center, CLINICAL CHARACTERISTICS, ELEVATION-MYOCARDIAL-INFARCTION, gender, MANAGEMENT, Factors sexuals en les malalties, Sex factors in disease
Abstract: Contains fulltext : 290798.pdf (Publisher’s version ) (Open Access) BACKGROUND: Several reports have demonstrated the impact of the COVID-19 pandemic on the management and outcome of patients with ST-segment elevation myocardial infarction (STEMI). The aim of the current analysis is to investigate the potential gender difference in the effects of the COVID-19 pandemic on mechanical reperfusion and 30-day mortality for STEMI patients within the ISACS-STEMI COVID-19 Registry. METHODS: This retrospective multicenter registry was performed in high-volume primary percutaneous coronary intervention (PPCI) centers on four continents and included STEMI patients undergoing PPCIs in March-June 2019 and 2020. Patients were divided according to gender. The main outcomes were the incidence and timing of the PPCI, (ischemia time ≥ 12 h and door-to-balloon ≥ 30 min) and in-hospital or 30-day mortality. RESULTS: We included 16683 STEMI patients undergoing PPCIs in 109 centers. In 2020 during the pandemic, there was a significant reduction in PPCIs compared to 2019 (IRR 0.843 (95% CI: 0.825-0.861, p < 0.0001). We did not find a significant gender difference in the effects of the COVID-19 pandemic on the numbers of STEMI patients, which were similarly reduced from 2019 to 2020 in both groups, or in the mortality rates. Compared to prepandemia, 30-day mortality was significantly higher during the pandemic period among female (12.1% vs. 8.7%; adjusted HR [95% CI] = 1.66 [1.31-2.11], p < 0.001) but not male patients (5.8% vs. 6.7%; adjusted HR [95% CI] = 1.14 [0.96-1.34], p = 0.12). CONCLUSIONS: The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a 16% reduction in PPCI procedures similarly observed in both genders. Furthermore, we observed significantly increased in-hospital and 30-day mortality rates during the pandemic only among females. Trial registration number: NCT 04412655.
Published: 2023

30. Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI

Author: Giuseppe De Luca, Pierre Deharo, Pierfrancesco Agostoni, Gabriele Gabrielli, Francisco Bosa Ojeda, Ylitalo Antti, Lisette Okkels Jensen, Bor Wilbert, Luigi Vignali, Fortunato Scotto Di Uccio, Dariusz Dudek, Marco Boccalatte, Monica Verdoia, Edouard Benit, Gianni Casella, Heidi Lehtola, Alessandra Scoccia, Tim Kinnaird, Massimo Siviglia, Raul Moreno, Vladimir Ganyukov, Arpad Lux, Mika Laine, Adrian P. Banning, Santiago Camacho-Freiere, Guido Parodi, José Moreu, Michał Kidawa, Miha Cercek, Victor Becerra, Stephane Manzo, Elvin Kedhi, Marija Vavlukis, Filippo Zilio, Ciro De Simone, Nikola Bakraceski, Xavier Carrillo, Giuseppe Uccello, Maurizio Menichelli, Gerard Rourai Ferrer, Dimitrios Alexopoulos, Benjamin Faurie, Jurriën M. ten Berg, Lucia Marinucci, Juan Sanchis Forés, Giovanni Amoroso, Sébastien Levesque, Bernardo Tuccillo, Enrico Fabris, Peter Ludman, Rui Campante Teles, Wojtek Wojakowski, Leonardo Spedicato, Lucian Calmac, Yves Cottin, Maurits T. Dirksen, Petr Kala, Thomas W Johnson, Xacobe Flores Rios, Gianluca Caiazzo, Clemens van Birgelen, Francesco Versaci, Alexander Ijsselmuiden, Luca Donazzan, Kees-Jan Royaards, Adriaan O. Kraaijeveld, Alejandro Gutierrez Barrios, Gennaro Galasso, Vincenzo Guiducci, Julinda Mehilli, Giuseppe Cirrincione, Andrea Santucci, Giuliana Cortese, José Luis Díez Gil, Iñigo Lozano Martínez-Luengas, Bruno Scheller, Periklis Davlouros, Tomas Kovarnik, Arturo García-Touchard, Pieter C. Smits, De Luca, G., Verdoia, M., Cercek, M., Jensen, L. O., Vavlukis, M., Calmac, L., Johnson, T., Ferrer, G. R., Ganyukov, V., Wojakowski, W., Kinnaird, T., van Birgelen, C., Cottin, Y., Ijsselmuiden, A., Tuccillo, B., Versaci, F., Royaards, K. -J., Berg, J. T., Laine, M., Dirksen, M., Siviglia, M., Casella, G., Kala, P., Diez Gil, J. L., Banning, A., Becerra, V., De Simone, C., Santucci, A., Carrillo, X., Scoccia, A., Amoroso, G., Lux, A., Kovarnik, T., Davlouros, P., Mehilli, J., Gabrielli, G., Rios, X. F., Bakraceski, N., Levesque, S., Cirrincione, G., Guiducci, V., Kidawa, M., Spedicato, L., Marinucci, L., Ludman, P., Zilio, F., Galasso, G., Fabris, E., Menichelli, M., Garcia-Touchard, A., Manzo, S., Caiazzo, G., Moreu, J., Fores, J. S., Donazzan, L., Vignali, L., Teles, R., Benit, E., Agostoni, P., Bosa Ojeda, F., Lehtola, H., Camacho-Freiere, S., Kraaijeveld, A., Antti, Y., Boccalatte, M., Deharo, P., Martinez-Luengas, I. L., Scheller, B., Alexopulos, D., Moreno, R., Kedhi, E., Uccello, G., Faurie, B., Gutierrez Barrios, A., Di Uccio, F. S., Wilbert, B., Smits, P., Cortese, G., Parodi, G., Dudek, D., banning, adrian/0000-0002-2842-7861, GUIDUCCI, VINCENZO/0000-0002-0833-2785, vavlukis, marija/0000-0002-4479-6691, Bor, Willem L/0000-0002-3253-5961, DAVLOUROS, PERIKLIS/0000-0002-1439-1992, Uccello, Giuseppe/0000-0002-6163-8468, Kidawa, Michal/0000-0002-5000-6561, [De Luca, Giuseppe] Univ Piemonte Orientale, Div Cardiol, Azienda Osped Univ Maggiore Carita, Novara, Italy, [Verdoia, Monica] Osped Inferm Biella, ASL Biella, Div Cardiol, Biella, Italy, [Cercek, Miha] Univ Med Ctr, Ctr Intens Internal Med, Ljubljana, Slovenia, [Jensen, Lisette Okkels] Odense Univ Hosp, Div Cardiol, Odense, Denmark, [Vavlukis, Marija] Ss Cyril & Methodius Univ, Med Fac, Univ Clin Cardiol, Skopje, North Macedonia, [Calmac, Lucian] Clin Emergency Hosp Bucharest, Bucharest, Romania, [Johnson, Tom] Univ Hosp Bristol NHSFT, Bristol Heart Inst, Div Cardiol, Bristol, Avon, England, [Johnson, Tom] Univ Bristol, Bristol, Avon, England, [Ferrer, Gerard Rourai] Hosp Univ Bellvitge, Heart Dis Inst, Intervent Cardiol Unit, Barcelona, Spain, [Ganyukov, Vladimir] State Res Inst Complex Issues Cardiovasc Dis, Div Cardiol, Kemerovo, Russia, [Wojakowski, Wojtek] Med Univ Silezia, Div Cardiol, Katowice, Poland, [Kinnaird, Tim] Univ Hosp Wales, Div Cardiol, Cardiff, Wales, [van Birgelen, Clemens] Thoraxctr Twente, Dept Cardiol, Med Spectrum Twente, Enschede, Netherlands, [Cottin, Yves] Univ Hosp, Div Cardiol, Dijon, France, [IJsselmuiden, Alexander] Amphia Hosp, Div Cardiol, Breda, Netherlands, [Tuccillo, Bernardo] Osped Mare, Div Cardiol, Naples, Italy, [Di Uccio, Fortunato Scotto] Osped Mare, Div Cardiol, Naples, Italy, [Versaci, Francesco] Osped Santa Maria Goretti, Div Cardiol, Latina, Italy, [Royaards, Kees-Jan] Maasstad Ziekenhuis, Div Cardiol, Rotterdam, Netherlands, [Smits, Pieter] Maasstad Ziekenhuis, Div Cardiol, Rotterdam, Netherlands, [Ten Berg, Jurrien] St Antonius Hosp, Div Cardiol, Nieuwegein, Netherlands, [Wilbert, Bor] St Antonius Hosp, Div Cardiol, Nieuwegein, Netherlands, [Laine, Mika] Helsinki Univ Cent Hosp, Div Cardiol, Helsinki, Finland, [Dirksen, Maurits] Northwest Clin, Div Cardiol, Alkmaar, Netherlands, [Siviglia, Massimo] Osped Riuniti Reggio Calabria, Div Cardiol, Reggio Di Calabria, Italy, [Casella, Gianni] Osped Maggiore Bologna, Div Cardiol, Bologna, Italy, [Kala, Petr] Masaryk Univ, Univ Hosp Brno, Med Fac, Brno, Czech Republic, [Diez Gil, Jose Luis] H Univ & Politecn La Fe, Valencia, Spain, [Banning, Adrian] John Radcliffe Hosp, Oxford, England, [Becerra, Victor] Hosp Clin Univ Virgen Victoria, Malaga, Spain, [De Simone, Ciro] Clin Villa Fiori, Div Cardiol, Acerra, Italy, [Santucci, Andrea] Osped Santa Maria Misericordia, Perugia, Italy, [Carrillo, Xavier] Hosp Germans Triasi Pujol, Badalona, Spain, [Scoccia, Alessandra] Osped St Anna, Div Cardiol, Ferrara, Italy, [Amoroso, Giovanni] Onze Lieve Vrouwe Gasthuis OLVG, Amsterdam, Netherlands, [Lux, Arpad] Mastricht Univ, Med Ctr, Maastricht, Netherlands, [Kovarnik, Tomas] Charles Univ Hosp, Prague, Czech Republic, [Davlouros, Periklis] Patras Univ Hosp, Invas Cardiol & Congenital Heart Dis, Patras, Greece, [Mehilli, Julinda] Ludwig Maximilians Univ Munchen, Univ Hosp Munich, Munich, Germany, [Gabrielli, Gabriele] Azienda Osped Univ, Intervent Cardiol Unit, Osped Riuniti, Ancona, Italy, [Rios, Xacobe Flores] Complexo Hosp Univ La Coruna, La Coruna, Spain, [Bakraceski, Nikola] Ctr Cardiovasc Dis, Ohrid, North Macedonia, [Levesque, Sebastien] CHU Poitiers, Univ Hosp, Poitiers, France, [Cirrincione, Giuseppe] Osped Civ Arnas, Div Cardiol, Palermo, Italy, [Guiducci, Vincenzo] AUSL IRCCS, Reggio Emilia, Italy, [Kidawa, Michal] Med Univ Lodz, Cent Hosp, Lodz, Poland, [Spedicato, Leonardo] Osped Santa Maria Misericordia, Div Cardiol, Udine, Italy, [Marinucci, Lucia] Osped Riuniti Marche Nord, Div Cardiol, Azienda Osped, Pesaro, Italy, [Ludman, Peter] Univ Hosp Birmingham, Birmingham, W Midlands, England, [Zilio, Filippo] Osped Santa Chiara, Trento, Italy, [Galasso, Gennaro] Osped San Giovanni Dio Ruggi Aragona, Div Cardiol, Salerno, Italy, [Fabris, Enrico] Univ Ospedali Riuniti, Azienda Osped, Trieste, Italy, [Menichelli, Maurizio] Osped F Spaziani, Div Cardiol, Frosinone, Italy, [Garcia-Touchard, Arturo] Hosp Puerta Hierro, Div Cardiol, Majadahonda, Spain, [Manzo, Stephane] Paris 07 Univ, CHU Lariboisiere, AP HP, Div Cardiol,INSERM,UMRS 942, Paris, France, [Caiazzo, Gianluca] Osped G Moscati, Div Cardiol, Aversa, Italy, [Moreu, Jose] Complejo Hosp Toledo, Div Cardiol, Toledo, Spain, [Sanchis Fores, Juan] Hosp Clin Univ Valencia, Div Cardiol, Valencia, Spain, [Donazzan, Luca] Osped S Maurizio Bolzano, Div Cardiol, Bolzano, Italy, [Vignali, Luigi] Azienda Osped Sanitaria, Intervent Cardiol Unit, Parma, Italy, [Teles, Rui] Hosp Santa Cruz, Div Cardiol, CHLO Carnaxide, Lisbon, Portugal, [Benit, Edouard] Jessa Ziekenhuis, Div Cardiol, Hasselt, Belgium, [Agostoni, Pierfrancesco] Ziekenhuis Netwerk Antwerpen ZNA Middelheim, Div Cardiol, Antwerp, Belgium, [Bosa Ojeda, Francisco] Hosp Univ Canarias, Div Cardiol, Santa Cruz De Tenerife, Spain, [Lehtola, Heidi] Oulu Univ Hosp, Div Cardiol, Oulu, Finland, [Camacho-Freiere, Santiago] Juan Ramon Jimenez Hosp, Div Cardiol, Huelva, Spain, [Kraaijeveld, Adriaan] UMC Utrecht, Div Cardiol, Utrecht, Netherlands, [Antti, Ylitalo] Univ Hosp, Heart Ctr, Div Cardiol, Turku, Finland, [Boccalatte, Marco] Osped Santa Maria Grazie, Div Cardiol, Pozzuoli, Italy, [Deharo, Pierre] Aix Marseille Univ, CHU Timone, Div Cardiol, Marseille, France, [Lozano Martinez-Luengas, Inigo] Hosp Cabuenes, Div Cardiol, Gijon, Spain, [Scheller, Bruno] Univ Saarland, Div Cardiol Clin & Expt Intervent Cardiol, Homburg, Germany, [Alexopoulos, Dimitrios] Attikon Univ Hosp, Div Cardiol, Athens, Greece, [Moreno, Raul] Hosp Paz, Div Cardiol, Madrid, Spain, [Kedhi, Elvin] St Jan Hosp, Div Cardiol, Brugge, Belgium, [Uccello, Giuseppe] Osped A Manzoni Lecco, Div Cardiol, Lecce, Italy, [Faurie, Benjamin] Grp Hosp Mutualiste Grenoble, Div Cardiol, Grenoble, France, [Gutierrez Barrios, Alejandro] Hosp Puerta Mar, Div Cardiol, Cadiz, Spain, [Cortese, Giuliana] Univ Padua, Dept Stat Sci, Padua, Italy, [Parodi, Guido] Azienda Osped Univ Sassari, Sassari, Italy, [Dudek, Dariusz] Jagiellonian Univ Med Coll, Inst Cardiol, Krakow, Poland, RS: Carim - H01 Clinical atrial fibrillation, and Cardiologie
Subjects: Male, Internationality, medical decision-making, medicine.medical_treatment, 030204 cardiovascular system & hematology, Rate ratio, COVID-19 (coronavirus), Settore MED/06, 0302 clinical medicine, Pandemic, Percutaneous Coronary Intervention/statistics & numerical data, Medicine, Viral, 030212 general & internal medicine, Myocardial infarction, Registries, Acute myocardial-infarction, Original Investigation, STEMI, ST-segment elevation myocardial infarction, Middle Aged, 3. Good health, Europe, fibrinolysis, Female, COVID-19, primary angioplasty, STEMI, Aged, Humans, Percutaneous Coronary Intervention, Retrospective Studies, ST Elevation Myocardial Infarction, Coronavirus Infections, Pandemics, Pneumonia, Viral, Cardiology and Cardiovascular Medicine, Editorial Comment, ACUTE MYOCARDIAL-INFARCTION, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Primary angioplasty, IRR, incidence rate ratio, Europe/epidemiology, 03 medical and health sciences, Betacoronavirus, cardiovascular diseases, Mortality, PCI, percutaneous coronary intervention, DES, drug-eluting stent(s), business.industry, ST Elevation Myocardial Infarction/mortality, PPCI, primary PCI, SARS-CoV-2, MORTALITY, Percutaneous coronary intervention, Retrospective cohort study, Pneumonia, medicine.disease, Confidence interval, ST-segment elevation myocardial infarction, CI, confidence interval, Emergency medicine, COVID-19, STEMI, primary angioplasty, ACS, acute coronary syndrome, business
Abstract: Background The fear of contagion during the coronavirus disease-2019 (COVID-19) pandemic may have potentially refrained patients with ST-segment elevation myocardial infarction (STEMI) from accessing the emergency system, with subsequent impact on mortality. Objectives The ISACS-STEMI COVID-19 registry aims to estimate the true impact of the COVID-19 pandemic on the treatment and outcome of patients with STEMI treated by primary percutaneous coronary intervention (PPCI), with identification of “at-risk” patient cohorts for failure to present or delays to treatment. Methods This retrospective registry was performed in European high-volume PPCI centers and assessed patients with STEMI treated with PPPCI in March/April 2019 and 2020. Main outcomes are the incidences of PPCI, delayed treatment, and in-hospital mortality. Results A total of 6,609 patients underwent PPCI in 77 centers, located in 18 countries. In 2020, during the pandemic, there was a significant reduction in PPCI as compared with 2019 (incidence rate ratio: 0.811; 95% confidence interval: 0.78 to 0.84; p, Central Illustration
Published: 2020

31. Impact of SARS-CoV-2 positivity on clinical outcome among STEMI patients undergoing mechanical reperfusion: Insights from the ISACS STEMI COVID 19 registry

Author: Pierre Deharo, Pieter C. Smits, Giuseppe De Luca, Luigi Vignali, Clemens von Birgelen, Michał Kidawa, Lucia Marinucci, Gabriele Gabrielli, Miha Cercek, Francisco Bosa Ojeda, Bernardo Tuccillo, Lisette Okkels Jensen, Gennaro Galasso, Vincenzo Guiducci, Pierfrancesco Agostoni, Monica Verdoia, Edouard Benit, Ewout Bruwiere, Massimo Siviglia, Maurizio Menichelli, Heidi Lehtola, Stephane Manzo, Benjamin Faurie, Filippo Zilio, Gerard Rourai Ferrer, José Moreu, Guido Parodi, Ylitalo Antti, Rui Campante Teles, Giovanni Amoroso, Jurriën M. ten Berg, Sébastien Levesque, Bor Wilbert, Fortunato Scotto Di Uccio, Maurits T. Dirksen, Raul Moreno, Kees Jan Royaards, Xavier Carrillo, Giuseppe Uccello, Alejandro Gutierrez Barrios, Lucian Calmac, Victor Becerra, Petr Kala, Thomas W Johnson, Wojtek Wojakowski, Marija Vavlukis, Leonardo Spedicato, Adriaan O. Kraaijeveld, Francesco Versaci, Marco Boccalatte, Xacobe Flores Rios, Alessandra Scoccia, Arnoud W J van 't Hof, Efthymia Varytimiadi, Peter Ludman, José Luis Díez Gil, Tomas Kovarnik, Gianni Casella, Tim Kinnaird, Adrian P. Banning, Vladimir Ganyukov, Arturo García-Touchard, Marek Milewski, Ciro De Simone, Nikola Bakraceski, Julinda Mehilli, Giuseppe Cirrincione, Grigorios Tsigkas, Juan Sanchis Forés, Andrea Santucci, Elvin Kedhi, Gianluca Caiazzo, Luca Donazzan, Alexander Ijsselmuiden, Iñigo Lozano Martínez-Luengas, Bruno Scheller, Enrico Fabris, Mika Laine, Yves Cottin, Niels Debel, Santiago Camacho-Freiere, Health Technology & Services Research, RS: Carim - H01 Clinical atrial fibrillation, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), HUS Heart and Lung Center, Kardiologian yksikkö, De Luca, G., Debel, N., Cercek, M., Jensen, L. O., Vavlukis, M., Calmac, L., Johnson, T., Ferrer, G. R., Ganyukov, V., Wojakowski, W., Kinnaird, T., von Birgelen, C., Cottin, Y., Ijsselmuiden, A., Tuccillo, B., Versaci, F., Royaards, K. -J., Berg, J. T., Laine, M., Dirksen, M., Siviglia, M., Casella, G., Kala, P., Diez Gil, J. L., Banning, A., Becerra, V., De Simone, C., Santucci, A., Carrillo, X., Scoccia, A., Amoroso, G., van't Hof, A. W., Kovarnik, T., Tsigkas, G., Mehilli, J., Gabrielli, G., Rios, X. F., Bakraceski, N., Levesque, S., Cirrincione, G., Guiducci, V., Kidawa, M., Spedicato, L., Marinucci, L., Ludman, P., Zilio, F., Galasso, G., Fabris, E., Menichelli, M., Garcia-Touchard, A., Manzo, S., Caiazzo, G., Moreu, J., Fores, J. S., Donazzan, L., Vignali, L., Teles, R., Benit, E., Agostoni, P., Ojeda, F. B., Lehtola, H., Camacho-Freiere, S., Kraaijeveld, A., Antti, Y., Boccalatte, M., Deharo, P., Martinez-Luengas, I. L., Scheller, B., Varytimiadi, E., Moreno, R., Uccello, G., Faurie, B., Gutierrez Barrios, A., Milewski, M., Bruwiere, E., Smits, P., Wilbert, B., Di Uccio, F. S., Parodi, G., Kedhi, E., Verdoia, M., vavlukis, marija/0000-0002-4479-6691, banning, adrian/0000-0002-2842-7861, Agostoni, Pierfrancesco/0000-0002-1505-9369, Jensen, Lisette Okkels/0000-0002-4838-2429, Cercek, Miha/0000-0001-6193-0349, Milewski, Marek/0000-0001-5459-9125, Johnson, Thomas/0000-0003-4638-601X, and Calmac, Lucian/0000-0002-3031-8023
Subjects: Registrie, ST Elevation Myocardial Infarction/diagnosis, medicine.medical_treatment, PRIMARY ANGIOPLASTY, 030204 cardiovascular system & hematology, SARS-CoV-2, ST segment elevation myocardial infarction, 0302 clinical medicine, Retrospective Studie, Registries, 030212 general & internal medicine, Myocardial infarction, skin and connective tissue diseases, THROMBUS ASPIRATION, Percutaneous Coronary Intervention/adverse effects, Thrombosis(please add them), education.field_of_study, Thrombosis, 3. Good health, Treatment Outcome, Cardiology and Cardiovascular Medicine, Human, medicine.medical_specialty, Humans, Reperfusion, Retrospective Studies, COVID-19, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction, Population, Article, 03 medical and health sciences, Internal medicine, medicine, cardiovascular diseases, Platelet activation, education, METAANALYSIS, business.industry, MORTALITY, ELEVATION MYOCARDIAL-INFARCTION, Percutaneous coronary intervention, Retrospective cohort study, medicine.disease, body regions, 3121 General medicine, internal medicine and other clinical medicine, Heart failure, Conventional PCI, business
Abstract: Background and aims SARS-Cov-2 predisposes patients to thrombotic complications, due to excessive inflammation, endothelial dysfunction, platelet activation, and coagulation/fibrinolysis disturbances. The aim of the present study was to evaluate clinical characteristics and prognostic impact of SARS-CoV-2 positivity among STEMI patients undergoing primary percutaneous coronary intervention (PPCI). Methods We selected SARS-CoV-2 positive patients included in the ISACS-STEMI COVID-19, a retrospective multicenter European registry including 6609 STEMI patients treated with PPCI from March 1st until April 30th, in 2019 and 2020. As a reference group, we randomly sampled 5 SARS-Cov-2 negative patients per each SARS-CoV-2 positive patient, individually matched for age, sex, and hospital/geographic area. Study endpoints were in-hospital mortality, definite stent thrombosis, heart failure. Results Our population is represented by 62 positive SARS-CoV-2 positive patients who were compared with a matched population of 310 STEMI patients. No significant difference was observed in baseline characteristics or the modality of access to the PCI center. In the SARS-CoV-2 positive patients, the culprit lesion was more often located in the RCA (p, Graphical abstract Image 1
Published: 2021

32. The role of ultrasonography in differential diagnosis of orbital lesions

Author: Camilla Russo, Giovanni Uccello, Fausto Tranfa, Vittoria Lanni, Diego Strianese, Gianfranco Vallone, Adriana Iuliano, Federica Fossataro, Lanni, V., Iuliano, A., Fossataro, F., Russo, C., Uccello, G., Tranfa, F., Strianese, D., and Vallone, G.
Subjects: medicine.medical_specialty, genetic structures, Lymphoma, Vascular malformations, Biopsy, Malignancy, 030218 nuclear medicine & medical imaging, Diagnosis, Differential, 03 medical and health sciences, 0302 clinical medicine, Idiopathic orbital inflammation, Orbital lesions, Ultrasonography, Humans, Orbital Diseases, Orbital lesion, Histological diagnosis, Diagnosis, Internal Medicine, medicine, Radiology, Nuclear Medicine and imaging, Original Paper, medicine.diagnostic_test, business.industry, Ultrasound, General Medicine, medicine.disease, eye diseases, Differential, 030221 ophthalmology & optometry, sense organs, Radiology, Differential diagnosis, business, True positive rate
Abstract: AIMS: The aim of this study is to assess the value of ultrasound in the differential diagnosis of orbital lesions. METHODS: One hundred and thirty-eight patients with clinical features of an orbital mass were examined by orbital ultrasound prior to undergoing surgery, from January 2000 to January 2017. All patients underwent excisional or incisional orbital biopsy. The results of orbital ultrasonography were compared with the final histological diagnosis. RESULTS: Orbital lesions were localized by ultrasonography in 133/138 cases (96.4%); the false-negative rate of orbital echography was 3.6% (5/138). The nature of the orbital lesions was correctly determined by ultrasonography in 54.3% of the cases (75/138) preoperatively (true positives). In 58/138 (42%) patients, there was no correspondence between the ultrasound diagnosis and the histological diagnosis (false positives). The sensitivity of orbital ultrasonography for the detection of an orbital mass was 93.75% (CI 87.87–99.63%), while the specificity yielded no meaningful result (CI 0.00–60.24%). Moreover, the specificity of orbital ultrasonography to identify a malignant tumor falls within a CI of 0–62.72%. CONCLUSIONS: Orbital ultrasonography is a rapid and noninvasive test that is highly sensitive in displaying an orbital mass; however, the specificity in the differential diagnosis of orbital lesions is not meaningful, particularly if malignancy is suspected. The assessment of orbital diseases requires multiple diagnostic approaches to balance the strengths and weaknesses of each method.
Published: 2021

33. Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

Author: Nicola Cascavilla, Monica Galli, Mario Boccadoro, Dominella Gangemi, Silvia Mangiacavalli, Massimo Offidani, Anna Grazia Recchia, Elena Zamagni, Angelo Belotti, Alessandra Pompa, Claudio Cerchione, Giuseppina Uccello, Paola Curci, Catello Califano, Concetta Conticello, Elena Rossi, Maria Teresa Petrucci, Valerio De Stefano, Giovanni Tripepi, Ugo Consoli, Enrico Attingenti, Marino Brunori, Stelvio Ballanti, Clelia Criscuolo, Nicola Giuliani, Michele Cavo, Renato Zambello, Vincenzo Ludovico Fraticelli, Giorgina Specchia, Angela Bonalumi, Francesca Patriarca, Nicola Di Renzo, Alessandra Lombardo, Salvatore Palmieri, Elisabetta Antonioli, Cirino Botta, Agostina Siniscalchi, Raffaella Stocchi, Barbara Gamberi, Ferdinando Frigeri, Massimo Gentile, Giuseppe Mele, Ernesto Vigna, Pellegrino Musto, Donatella Vincelli, Silvana Capalbo, Annalisa Pitino, Sara Bringhen, Daniele Derudas, Francesco Di Raimondo, Massimo Martino, Roberto Ria, Alfredo Gagliardi, Gianpaolo Marcacci, Fortunato Morabito, Stefano Rocco, Gentile M., Specchia G., Derudas D., Galli M., Botta C., Rocco S., Conticello C., Califano C., Giuliani N., Mangiacavalli S., Attingenti E., Lombardo A., Brunori M., Rossi E., Antonioli E., Ria R., Zambello R., Di Renzo N., Mele G., Marcacci G., Musto P., Capalbo S., Cascavilla N., Cerchione C., Belotti A., Criscuolo C., Uccello G., Curci P., Vigna E., Fraticelli V., Vincelli D., Bonalumi A., Siniscalchi A., Stocchi R., Martino M., Ballanti S., Gangemi D., Gagliardi A., Gamberi B., Pompa A., Recchia A.G., Tripepi G., Pitino A., Frigeri F., Consoli U., Bringhen S., Zamagni E., Patriarca F., De Stefano V., Di Raimondo F., Palmieri S., Petrucci M.T., Offidani M., Boccadoro M., Cavo M., and Morabito F.
Subjects: Oncology, medicine.medical_specialty, Elotuzumab, lenalidomide, dexamethasone, salvage therapy, multiple myeloma, Salvage therapy, Antibodies, Monoclonal, Humanized, Antibodies, Dexamethasone, Efficacy, Internal medicine, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Progression-free survival, Elotuzumab, Letters to the Editor, Elotuzumab, lenalidomide, dexamethasone, multiple myeloma, Humanized, Lenalidomide, Multiple myeloma, Retrospective Studies, Salvage Therapy, business.industry, Retrospective cohort study, Hematology, medicine.disease, Clinical trial, Italy, Multiple Myeloma, business, medicine.drug
Abstract: No abstract available
Published: 2021

34. Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry

Author: Gianluca Caiazzo, Giuseppe De Luca, Sébastien Levesque, Victor Becerra, Filippo Zilio, Gabriele Gabrielli, Xacobe Flores Rios, José Moreu, Tomas Kovarnik, Wojtek Wojakowski, Juan Sanchis Forés, Luca Donazzan, Dimitrios Alexopoulos, Gerard Rourai Ferrer, Luigi Vignali, Alessandra Scoccia, Giuseppe Uccello, Lucia Marinucci, Marco Boccalatte, Lisette Okkels Jensen, Enrico Fabris, Michał Kidawa, Miha Cercek, Ylitalo Antti, Stephane Manzo, Lucian Calmac, Gennaro Galasso, Vincenzo Guiducci, Iñigo Lozano Martínez-Luengas, Petr Kala, Elvin Kedhi, Bruno Scheller, Monica Verdoia, Bor Wilbert, Maurizio Menichelli, Benjamin Faurie, Thomas W Johnson, Alejandro Gutierrez Barrios, José Luis Díez Gil, Giuliana Cortese, Clemens von Birgelen, Guido Parodi, Raul Moreno, Francesco Versaci, Arpad Lux, Santiago Camacho-Freiere, Xavier Carrill, Periklis Davlouros, Mika Laine, Adriaan O. Kraaijeveld, Heidi Lehtola, Jurriën M. ten Berg, Gianni Casella, Vladimir Ganyukov, Ciro De Simone, Nikola Bakraceski, Rui Campante Teles, Maurits T. Dirksen, Francisco Bosa Ojeda, Marija Vavlukis, RS: Carim - H01 Clinical atrial fibrillation, Cardiologie, [De Luca,G, Verdoia,M] Division of Cardiology, Azienda Ospedaliero-Universitaria Maggiore della Carità, Università del Piemonte Orientale, Novara, Italy. giuseppe.deluca@med.uniupo.it. [Cercek,M] Centre for Intensive Internal Medicine, University Medical Centre, Ljubljana, Slovenia. [Jensen,LO] Division of Cardiology, Odense Universitets Hospital, Odense, Danemark. [Vavlukis,M] University Clinic for Cardiology, Medical Faculty, Ss' Cyril and Methodius University, Skopje, North Macedonia. [Calmac,L] Clinic Emergency Hospital of Bucharest, Bucharest, Romania. [Johnson,T] Division of Cardiology, Bristol Heart Institute, University Hospitals Bristol, NHSFT & University of Bristol, Bristol, UK. [Roura i Ferrer,G] Interventional Cardiology Unit, Heart Disease Institute, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain. [Ganyukov,V] 8Division of Cardiology, State Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia. [Wojakowski,W] Division of Cardiology, Medical University of Silezia, Katowice, Poland. [von Birgelen,C] Department of Cardiology, Medisch Spectrum Twente, Thoraxcentrum Twente, Enschede, The Netherlands. [Versaci,F] Division of Cardiology, Ospedale Santa Maria Goretti, Latina, Italy. [Ten Berg,J] Division of Cardiology, St Antonius Hospital, Nieuwegein, The Netherlands. [Laine,L] Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. [Dirksen,M] Division of Cardiology, Northwest Clinic, Alkmaar, The Netherlands. [Casella,G] Division of Cardiology, Ospedale Maggiore, Bologna, Italy. [Kala,P] University Hospital Brno, Medical Faculty of Masaryk University Brno, Brno, Czech Republic. [Díez Gil,JL] H. Universitario y Politécnico La Fe, Valencia, Spain. [Becerra,V] Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain. [De Simone,C] Division of Cardiology, Clinica Villa dei Fiori, Acerra, Italy. [Carrill,X] Hospital Germans Triasi Pujol, Badalona, Spain. [Scoccia,A] Division of Cardiology, Ospedale 'Sant'Anna', Ferrara, Italy. [Lux,A] Maastricht University Medical Center, Maastricht, The Netherlands. [Kovarnik,T] University Hospital Prague, Prague, Czech Republic. [Davlouros,P] Invasive Cardiology and Congenital Heart Disease, Patras University Hospital, Patras, Greece. [Gabrielli,G] Interventional Cardiology Unit, Azienda Ospedaliero Universitaria 'Ospedali Riuniti', Ancona, Italy. [Flores Rios,X] Complexo Hospitaliero Universitario La Coruna, La Coruna, Spain. [Bakraceski,N] Center for Cardiovascular Diseases, Ohrid, North Macedonia. [Levesque,S] Center Hospitalier, Universitaire de Poitiers, University Hospital, Poitiers, France. [Guiducci,V] AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy. [Kidawa,M] Central Hospital of Medical University of Lodz, Łódź, Poland. [Marinucci,L] Division of Cardiology, AziendaOspedaliera 'Ospedali Riuniti Marche Nord', Pesaro, Italy. [Zilio,F] Ospedale Santa Chiara di Trento, Trento, Italy. [Galasso,G] Division of Cardiology, Ospedale San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy. [Fabris,E] Azienda Ospedaliero - Universitaria Ospedali Riuniti Trieste, Trieste, Italy. [Menichelli,M] Division of Cardiology, Ospedale 'F. Spaziani, Frosinone, Italy. [Manzo,S] Division of Cardiology, CHU Lariboisière, AP-HP, Paris VII University, INSERM UMRS 942, Paris, France. [Caiazzo,G] Division of Cardiology, Ospedale 'G Moscati', Aversa, Italy. [Moreu,J] Division of Cardiology, Complejo Hospitalario de Toledo, Toledo, Spain. [Sanchis Forés,J] Division of Cardiology, Hospital Clinico Universitario de Valencia, Valencia, Spain. [Donazzan,L] Division of Cardiology, Ospedale 'S. Maurizio' Bolzano Ospedale 'S. Maurizio', Bolzano, Italy. [Vignali,L] Interventional Cardiology Unit, Azienda Ospedaliera Sanitaria, Parma, Italy. [Teles,R] Division of Cardiology, Hospital de Santa Cruz, CHLO - Carnaxide, Carnaxide, Portugal. [Bosa Ojeda,F] Division of Cardiology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. [Lehtola,H] Division of Cardiology, Oulu University Hospital, Oulu, Finland. [Camacho‑Freiere,S] Division of Cardiology, Juan Ramon Jimenez Hospital, Huelva, Spain. [Kraaijeveld,A] Division of Cardiology, UMC Utrecht, Utrecht, The Netherlands. [Antti,Y] Division of Cardiology, Heart Centre Turku, Turku, Finland. [Boccalatte,M] Division of Cardiology, Ospedale Santa Maria delle Grazie, Pozzuoli, Italy. [Lozano Martínez‑Luengas,I] Division of Cardiology, Hospital Cabueñes, Gijon, Spain. [Scheller,B] Division of Cardiology, Clinical and Experimental Interventional Cardiology, University of Saarland, Saarbrücken, Germany. [Alexopoulos,D] Division of Cardiology, Attikon University Hospital, Athens, Greece. [Faurie,B] Division of Cardiology, Ospedale 'A. Manzoni' Lecco, Lecco, Italy. [Gutierrez Barrios,A] Division of Cardiology, Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France. [Wilbert,B] Division of Cardiology, Hospital Puerta del Mar, Cadiz, Spain. [Cortese,G] Department of Statistical Sciences, University of Padova, Padova, Italy. [Moreno,R] Division of Cardiology, Hospital la Paz, Madrid, Spain. [Parodi,G] Azienda Ospedaliero-Universitaria Sassari, Sassari, Italy. [Kedhi,E] Division of Cardiology, St-Jan Hospital, Brugge, Belgium. [Verdoia,M] Division of Cardiology, Ospedale degli Infermi, ASL Biella, Ponderano, Italy., HUS Heart and Lung Center, Kardiologian yksikkö, De Luca, G., Cercek, M., Jensen, L. O., Vavlukis, M., Calmac, L., Johnson, T., Roura i Ferrer, G., Ganyukov, V., Wojakowski, W., von Birgelen, C., Versaci, F., Ten Berg, J., Laine, M., Dirksen, M., Casella, G., Kala, P., Diez Gil, J. L., Becerra, V., De Simone, C., Carrill, X., Scoccia, A., Lux, A., Kovarnik, T., Davlouros, P., Gabrielli, G., Flores Rios, X., Bakraceski, N., Levesque, S., Guiducci, V., Kidawa, M., Marinucci, L., Zilio, F., Galasso, G., Fabris, E., Menichelli, M., Manzo, S., Caiazzo, G., Moreu, J., Sanchis Fores, J., Donazzan, L., Vignali, L., Teles, R., Bosa Ojeda, F., Lehtola, H., Camacho-Freiere, S., Kraaijeveld, A., Antti, Y., Boccalatte, M., Martinez-Luengas, I. L., Scheller, B., Alexopoulos, D., Uccello, G., Faurie, B., Gutierrez Barrios, A., Wilbert, B., Cortese, G., Moreno, R., Parodi, G., Kedhi, E., and Verdoia, M.
Subjects: Registrie, Male, lcsh:Diseases of the circulatory (Cardiovascular) system, Infarto del miocardio con elevación del ST, Time Factors, COVID-19/diagnosis, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective Studies [Medical Subject Headings], Phenomena and Processes::Physical Phenomena::Time::Time Factors [Medical Subject Headings], Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, PRIMARY ANGIOPLASTY, 030204 cardiovascular system & hematology, Rate ratio, Geographical Locations::Geographic Locations::Europe::Europe, Eastern [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Time-to-Treatment/trends, 0302 clinical medicine, Retrospective Studie, Risk Factors, Síndrome coronario agudo, 030212 general & internal medicine, Myocardial infarction, Hospital Mortality, Registries, Diabetes Mellitus/diagnosis, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Patient Care::Time-to-Treatment [Medical Subject Headings], Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings], Original Investigation, Percutaneous Coronary Intervention/adverse effects, Aged, COVID-19, Diabetes Mellitus, Europe, Female, Humans, Hypertension, Middle Aged, Percutaneous Coronary Intervention, Retrospective Studies, ST Elevation Myocardial Infarction, Time-to-Treatment, Treatment Outcome, Hospital Mortality/trends, Health Care::Health Services Administration::Organization and Administration::Records as Topic::Registries [Medical Subject Headings], education.field_of_study, Incidence (epidemiology), Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Cardiovascular Surgical Procedures::Vascular Surgical Procedures::Endovascular Procedures::Percutaneous Coronary Intervention [Medical Subject Headings], Diabetes Mellitu, Intervención coronaria percutánea, 3. Good health, surgical procedures, operative, Acute coronary syndrome, Cardiology and Cardiovascular Medicine, Human, medicine.medical_specialty, ACUTE MYOCARDIAL-INFARCTION, Time Factor, Population, Health Care::Environment and Public Health::Public Health::Epidemiologic Factors::Causality::Risk Factors [Medical Subject Headings], Europe/epidemiology, Diseases::Cardiovascular Diseases::Vascular Diseases::Hypertension [Medical Subject Headings], 03 medical and health sciences, Hypertension/epidemiology, Internal medicine, Diabetes mellitus, medicine, cardiovascular diseases, education, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings], Pandemia, Pandemic, Diseases::Endocrine System Diseases::Diabetes Mellitus [Medical Subject Headings], ST Elevation Myocardial Infarction/mortality, business.industry, Risk Factor, MORTALITY, Percutaneous coronary intervention, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Retrospective cohort study, medicine.disease, Diseases::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [Medical Subject Headings], lcsh:RC666-701, 3121 General medicine, internal medicine and other clinical medicine, Reperfusion, Conventional PCI, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality::Hospital Mortality [Medical Subject Headings], business
Abstract: Background It has been suggested the COVID pandemic may have indirectly affected the treatment and outcome of STEMI patients, by avoidance or significant delays in contacting the emergency system. No data have been reported on the impact of diabetes on treatment and outcome of STEMI patients, that was therefore the aim of the current subanalysis conducted in patients included in the International Study on Acute Coronary Syndromes–ST Elevation Myocardial Infarction (ISACS-STEMI) COVID-19. Methods The ISACS-STEMI COVID-19 is a retrospective registry performed in European centers with an annual volume of > 120 primary percutaneous coronary intervention (PCI) and assessed STEMI patients, treated with primary PCI during the same periods of the years 2019 versus 2020 (March and April). Main outcomes are the incidences of primary PCI, delayed treatment, and in-hospital mortality. Results A total of 6609 patients underwent primary PCI in 77 centers, located in 18 countries. Diabetes was observed in a total of 1356 patients (20.5%), with similar proportion between 2019 and 2020. During the pandemic, there was a significant reduction in primary PCI as compared to 2019, similar in both patients with (Incidence rate ratio (IRR) 0.79 (95% CI: 0.73–0.85, p p p Furthermore, the pandemic was independently associated with a significant increase in door-to-balloon and total ischemia times only among patients without diabetes, which may have contributed to the higher mortality, during the pandemic, observed in this group of patients. Conclusions The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a similar reduction in primary PCI procedures in both patients with and without diabetes. Hypertension had a significant impact on PCI reduction only among patients without diabetes. We observed a significant increase in ischemia time and door-to-balloon time mainly in absence of diabetes, that contributed to explain the increased mortality observed in this group of patients during the pandemic. Trial registration number: NCT 04412655.
Published: 2020

35. Primary cutaneous anaplastic large-cell lymphoma of the eyelid: report of two cases and review of the literature

Author: Silvia Varricchio, Adriana Iuliano, Maria Paola Laezza, Federica Fossataro, Massimo Mascolo, Diego Strianese, Giovanni Uccello, Fausto Tranfa, Vittoria Lanni, Iuliano, A., Fossataro, F., Laezza, M. P., Lanni, V., Mascolo, M., Varricchio, S., Uccello, G., Tranfa, F., and Strianese, D.
Subjects: medicine.medical_specialty, cutaneous anaplastic large cell lymphoma, Skin Neoplasms, CD30, Ki-1 Antigen, Primary cutaneous anaplastic large cell lymphoma, 03 medical and health sciences, 0302 clinical medicine, Lymphoma, Primary Cutaneous Anaplastic Large Cell, immune system diseases, hemic and lymphatic diseases, medicine, Humans, 030223 otorhinolaryngology, Aged, Solitary pulmonary nodule, business.industry, solitary nodule, Eyelids, medicine.disease, Dermatology, Adnexal tumor, Adnexal tumors, Lymphoma, Ocular oncology, Ophthalmology, medicine.anatomical_structure, eyelid, 030221 ophthalmology & optometry, Lymphoma, Large-Cell, Anaplastic, Eyelid, Neoplasm Recurrence, Local, business, ocular oncology
Abstract: Purpose: Two new cases of primary cutaneous CD30+ anaplastic large-cell lymphoma (cALCL) of the eyelid are reported; these are analysed alongside existing cases to identify challenges relating to the diagnosis and management of such rare lesions. Material and Methods: A review of existing literature on the PubMed database is conducted using the keywords: ‘eyelid lymphoid proliferations’, ‘lymphoma of the eyelid’, and ‘primary cutaneous CD30+, ALK-anaplastic large-cell lymphoma of the eyelid’. Two new cases of cALCL are reported. Cases where patients present solely with a nodular periocular lesion are analysed for recurrence and survival rate. Results: Two new patients with a painless ulcerated nodule on the upper eyelid receive a confirmed diagnosis of cALCL after undergoing an excisional biopsy. The first, elderly patient has spontaneous remission; the second patient, with a concomitant chronic infection of hepatitis C virus (HCV), presents a more diffuse disease at the onset and requires radiotherapy. Together with 13 patients a primary cALCL identified from 11 previous studies, this constitutes a cohort of 15 patients. Of these, 10 present with an exclusively nodular lesion of the eyelid and four experience disease recurrence; no deaths from cALCL are reported. Conclusion: Differential diagnosis between primary cALCL and lymphomatoid papulosis is essential and requires careful consideration of clinical and pathologic features. Radiologic staging examination is crucial in order to exclude systemic ALCL, particularly for patients with comorbidity. Though cALCL has the pathological features of a malignant lesion, the prognosis seems favourable for patients; a relatively high percentage even experience spontaneous resolution.
Published: 2020

36. Oculoplastic management of patients in the Covid-19 era: experience from an Italian tertiary referral center

Author: Maria Paola Laezza, Fausto Tranfa, Vittoria Lanni, Giovanni Uccello, Adriana Iuliano, Diego Strianese, Lanni, V., Iuliano, A., Laezza, M. P., Uccello, G., Tranfa, F., and Strianese, D.
Subjects: Blepharoplasty, Male, Reconstructive surgery, medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, Emergent care, Ophthalmologic Surgical Procedures, Tertiary Care Centers, 03 medical and health sciences, 0302 clinical medicine, Pandemic, medicine, Humans, Surgery, Plastic, 030223 otorhinolaryngology, Pandemics, Cross Infection, Elective Surgical Procedure, business.industry, Coronavirus Infection, COVID-19, oculoplastic, medicine.disease, ophthalmology, Italy, Elective Surgical Procedures, 030221 ophthalmology & optometry, Referral center, Ophthalmologic Surgical Procedure, Female, Medical emergency, Coronavirus Infections, business, guideline, Human
Abstract: In response to COVID-19 pandemic the European Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS) recommends to avoid any treatment unless urgent or emergent care, in order to reduce ...
Published: 2020

37. Risk factors for orbital exenteration in periocular Basal cell carcinoma.

Author: Iuliano A, Strianese D, Uccello G, Diplomatico A, Tebaldi S, and Bonavolontà G
Published: 2012

38. Adipokines, Vascular Wall, and Cardiovascular Disease

Author: Giovanni Esposito, Bruno Trimarco, Vito Di Palma, Giuseppe Uccello, Fabio Maresca, Alessandro Giaquinto, Michele Bevilacqua, Plinio Cirillo, Vittorio Taglialatela, Maresca, F1, Palma, Vd, Bevilacqua, M, Uccello, G, Taglialatela, V, Giaquinto, A, Trimarco, Bruno, and Esposito, Giovanni
Subjects: medicine.medical_specialty, vascular wall, Adipokine, Inflammation, Disease, Bioinformatics, acute coronary syndrome, atherosclerosi, Adipokines, cardiovascular disease, Non-alcoholic Fatty Liver Disease, Risk Factors, Internal medicine, Adipocytes, medicine, Animals, Humans, Obesity, Risk factor, Abdominal obesity, adipokine, business.industry, medicine.disease, Pathophysiology, Endocrinology, inflammation, Cardiovascular Diseases, Blood Vessels, Inflammation Mediators, medicine.symptom, Metabolic syndrome, Cardiology and Cardiovascular Medicine, business, Biomarkers, Signal Transduction
Abstract: Epidemiological evidence has shown that abdominal obesity is closely associated with the development of cardiovascular (CV) disease, suggesting that it might be considered as an independent CV risk factor. However, the pathophysiological mechanisms responsible for the association between these 2 clinical entities remain largely unknown. Adipocytes are considered able to produce and secrete chemical mediators known as “adipokines” that may exert several biological actions, including those on heart and vessels. Of interest, a different adipokine profile can be observed in the plasma of patients with obesity or metabolic syndrome compared with healthy controls. We consider the main adipokines, focusing on their effects on the vascular wall and analyzing their role in CV pathophysiology.
Published: 2014

39. An analysis of 2,480 space-occupying lesions of the orbit from 1976 to 2011

Author: Adriana Iuliano, Fausto Tranfa, Piergiacomo Grassi, Diego Strianese, Chiara Comune, Giovanni Uccello, Giulio Bonavolontà, Bonavolonta', Giulio, Strianese, Diego, Grassi, P, Comune, C, Tranfa, Fausto, Uccello, G, and Iuliano, A.
Subjects: Adult, Male, medicine.medical_specialty, genetic structures, Meningioma, Hemangioma, Quadrant (abdomen), Carcinoma, Medicine, Humans, Basal cell carcinoma, Mucocele, Neoplasm Metastasis, Dermoid Cyst, Retrospective Studies, business.industry, Lymphoma, Non-Hodgkin, General Medicine, medicine.disease, eye diseases, Basal cell epithelioma, Ophthalmology, Hemangioma, Cavernous, Dermoid cyst, Italy, Carcinoma, Basal Cell, Orbital Neoplasms, Surgery, Female, sense organs, Radiology, business
Abstract: Purpose To evaluate the frequencies of orbital space-occupying lesions seen at single orbital unit in a period of 35 years. Methods In this retrospective case series, the authors reviewed the medical records of 2,480 consecutive patients referred to the authors' Orbital Unit for evaluation of an orbital mass between 1976 and 2011. The final diagnosis in each case was established by a combination of history, ocular findings, diagnostic imaging, and histopathologic analysis, when available. The number and percentage of benign and malignant tumors were determinated, also according to the age of the patients and the tumor location within the orbit. This study adhered to the principles of the Declaration of Helsinki. Results Of the 2,480 lesions, 1,697 (68%) were benign and 783 (32%) were malignant. The most frequent benign tumors were dermoid cyst (14%) and cavernous hemangioma (9%). The most common malignant tumors were non-Hodgkin lymphoma (12%), basal cell carcinoma (3%), and orbital metastases (3%). In patients younger than 60 years, benign tumors are more frequent, whereas in patients older than 60 years, the frequency of malignant tumors increased. Regarding the distribution in the orbit, the most common tumors were dermoid cyst (206 cases) in the upper-outer quadrant, mucocele (155 cases) in the upper-inner quadrant, basal cell epithelioma (35 cases) in the lower-inner quadrant, cavernous hemangioma (68 cases) in the lower-outer quadrant, and meningioma (90 cases) in central space. Most of the tumors were located in the upper-outer quadrant. In the lower-inner quadrant, malignant tumors were more frequent than benign tumors. Conclusions The authors' findings highlight the distinctive nature of the orbital oncology experience at an ocular oncology department.
Published: 2013

40. Risk Factors for Orbital Exenteration in Periocular Basal Cell Carcinoma

Author: Agostino Diplomatico, Diego Strianese, Sabrina Tebaldi, Giulio Bonavolontà, Giovanni Uccello, Adriana Iuliano, Iuliano, A, Strianese, Diego, Uccello, G, Diplomatico, A, Tebaldi, S, Bonavolontà, G., Strianese, D, and Bonavolonta', Giulio
Subjects: Male, medicine.medical_specialty, Skin Neoplasms, Orbital exenteration, Orbital malignancy, Eyelid Neoplasms, Lesion, basal cell carcinoma, Risk Factors, medicine, Carcinoma, Humans, Neoplasm Invasiveness, Basal cell carcinoma, In patient, Orbit Evisceration, Survival rate, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Retrospective cohort study, Middle Aged, medicine.disease, Surgery, Survival Rate, exenteration orbitae, Ophthalmology, medicine.anatomical_structure, Carcinoma, Basal Cell, Orbital Neoplasms, Female, Eyelid, Neoplasm Recurrence, Local, medicine.symptom, business, Follow-Up Studies
Abstract: PURPOSE: To present the proportion of patients with periocular basal cell carcinoma (BCC) who underwent orbital exenteration and to evaluate the significance of the following risk factors: initial tumor site, pathologic features, and initial treatment. DESIGN: Retrospective, comparative, interventional case series. METHODS: Charts of all patients with BCC referred to Orbital Unit of the University of Naples "Federico II" between 1984 and 2003 were reviewed. Charts were reviewed for patient demographics, previous treatments, tumor site, clinical presentation, duration of symptoms, and histologic subtype. The main outcomes were recurrence rate, tumor-related deaths, orbital infiltration, and rate of exenteration. RESULTS: Data (including follow-up) were available for 506 patients. Twenty-eight patients (5.5%) underwent orbital exenteration. For 8 patients (28.5%), orbital exenteration was the first procedure performed. In the exenterated group, the most common tumor site was the medial cantus, whereas in the overall group, it was the lower eyelid (P = .001). The proportion of patients initially treated without margin control was significantly higher in patients undergoing exenteration (P = .0001). Pathologic examination revealed a higher incidence of infiltrative subtype in the exenterated group (P = .00019). CONCLUSIONS: The need for exenteration for BCC may be significantly higher when the lesion involves a medial canthal location, initial management does not include margin-controlled excision, or pathologic analysis reveals an infiltrative subtype. Margin-controlled excision for periocular BCC and close follow-up after excision for medial canthal BCC may be indicated.
Published: 2012

41. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.

Author: Martino EA, Palmieri S, Galli M, Derudas D, Mina R, Della Pepa R, Zambello R, Vigna E, Bruzzese A, Mangiacavalli S, Zamagni E, Califano C, Musso M, Conticello C, Cerchione C, Mele G, Di Renzo N, Offidani M, Tarantini G, Casaluci GM, Rago A, Ria R, Uccello G, Barilà G, Palumbo G, Pettine L, Vincelli ID, Brunori M, Accardi F, Amico V, Amendola A, Fontana R, Bongarzoni V, Rossini B, Cotzia E, Gozzetti A, Rizzi R, Sgherza N, Reddiconto G, Maroccia A, Franceschini L, Bertuglia G, Nappi D, Barbieri E, Gamberi B, Petrucci MT, Di Raimondo F, Neri A, Morabito F, Musto P, and Gentile M
Subjects: Humans, Male, Female, Aged, Middle Aged, Retrospective Studies, Follow-Up Studies, Aged, 80 and over, Adult, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local pathology, Drug Resistance, Neoplasm, Survival Rate, Multiple Myeloma drug therapy, Multiple Myeloma mortality, Multiple Myeloma pathology, Dexamethasone administration & dosage, Dexamethasone adverse effects, Dexamethasone therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Thalidomide analogs & derivatives, Thalidomide administration & dosage, Thalidomide adverse effects, Thalidomide therapeutic use
Abstract: The ELOQUENT-3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The present study is an 18-month follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloPd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 17.7 months, 213 patients (66.4%) experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 7.5 and 19.2 months, respectively. The updated multivariate analysis showed a significant reduction of PFS benefit magnitude both in advanced International Staging System (ISS) (II and III) stages and previous exposure to daratumumab cases. Instead, advanced ISS (II and III) stages and more than 2 previous lines of therapy maintained an independent prognostic impact on OS. Major adverse events included grade three-fourths neutropenia (24.9%), anemia (13.4%), lymphocytopenia (15.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 19.3% and 8.7%, respectively. A slight increase in the incidence of neutropenia and lymphocytopenia was registered with longer follow-up. In conclusion, our real-world study still confirms that EloPd is a safe and possible therapeutic choice for RRMM. Nevertheless, novel strategies are desirable for those patients exposed to daratumumab., (© 2024 John Wiley & Sons Ltd.)
Published: 2024
Full Text: View/download PDF

42. Pathophysiological Link and Treatment Implication of Heart Failure and Preserved Ejection Fraction in Patients with Chronic Kidney Disease.

Author: Bonacchi G, Rossi VA, Garofalo M, Mollace R, Uccello G, Pieragnoli P, Checchi L, Perrotta L, Voltolini L, Ricciardi G, and Beltrami M
Abstract: Heart failure with preserved ejection fraction (HFpEF) results from a complex interplay of age, genetic, cardiac remodeling, and concomitant comorbidities including hypertension, obesity, diabetes, and chronic kidney disease (CKD). Renal failure is an important comorbidity of HFpEF, as well as a major pathophysiological mechanism for those patients at risk of developing HFpEF. Heart failure (HF) and CKD are intertwined conditions sharing common disease pathways; the so-called "kidney tamponade", explained by an increase in intracapsular pressure caused by fluid retention, is only the latest model to explain renal injury in HF. Recognizing the different phenotypes of HFpEF remains a real challenge; the pathophysiological mechanisms of renal dysfunction may differ across the HF spectrum, as well as the prognostic role. A better understanding of the role of cardiorenal interactions in patients with HF in terms of symptom status, disease progression, and prognosis remains essential in HF management. Historically, patients with HF and CKD have been scarcely represented in clinical trial populations. Current concerns affect the practical approach to HF treatment, and, in this context, physicians are frequently hesitant to prescribe and titrate both new and old treatments. Therefore, the extensive application of HF drugs in diverse HF subtypes with numerous comorbidities and different renal dysfunction etiologies remains a controversial matter of discussion. Numerous recently introduced drugs, such as sodium-glucose-linked transporter 2 inhibitors (SGLT2i), constitute a new therapeutic option for patients with HF and CKD. Because of their protective vascular and hormonal actions, the use of these agents may be safely extended to patients with renal dysfunction in the long term. The present review delves into the phenotype of patients with HFpEF and CKD from a pathophysiological perspective, proposing a treatment approach that suggests a practical stepwise algorithm for the proper application of life-saving therapies in clinical practice.
Published: 2024
Full Text: View/download PDF

43. Case report: EBV-related eye orbits and sinuses lymphohistiocytic infiltration responsive to rituximab in a patient with X lymphoproliferative syndrome type 1.

Author: Giardino G, Lanni V, Mascolo M, Russo D, Cirillo E, Romano R, Cillo F, Grilli L, Prencipe MR, Iuliano A, Uccello G, De Fusco C, Menna G, Scalia G, Portella G, and Pignata C
Subjects: Child, Humans, Herpesvirus 4, Human, Rituximab, Epstein-Barr Virus Infections genetics, Lymphoproliferative Disorders, Lymphohistiocytosis, Hemophagocytic genetics, Lymphoma, Immunologic Deficiency Syndromes
Abstract: Background and Aims: X lymphoproliferative syndrome type 1 (XLP1) is a rare inborn error of immunity due to mutations of SH2D1A , encoding for slam-associated protein (SAP). The clinical phenotype includes severe mononucleosis, hemophagocytic lymphohistiocytosis (HLH), and B-cell lymphomas., Methods: We report the case of a child affected with XLP1 who presented with an incomplete HLH, triggered by Epstein-Barr virus (EBV) and treated with rituximab, involving orbits and paranasal sinuses., Results: The lesion was indistinguishable from lymphoma, complicating diagnosis and treatment. In addition, considering the high incidence of lymphoma in patients with XLP1, histology helped define its nature, driving therapeutic choices., Conclusion: We described an unusual presentation of incomplete HLH in a patient affected with XLP1: an EBV-driven infiltration of the orbits and paranasal sinuses. This led us to a challenging differential diagnosis of lymphoma-associated hemophagocytic syndrome, which can be frequently observed in patients with XLP1. Considering the extremely poor prognosis of this clinical finding, we sought for a prompt diagnosis and managed to obtain it and to immediately establish the right treatment on the basis of the pathological finding., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Giardino, Lanni, Mascolo, Russo, Cirillo, Romano, Cillo, Grilli, Prencipe, Iuliano, Uccello, De Fusco, Menna, Scalia, Portella and Pignata.)
Published: 2024
Full Text: View/download PDF

44. Contrast-zero transcatheter aortic valve replacement with ACURATE neo2™ system in patients with severe chronic kidney disease.

Author: Ielasi A, Buono A, Pellicano M, Briguglia D, Uccello G, Cortese B, DE Blasio G, Glauber M, Guagliumi G, and Tespili M
Subjects: Humans, Aortic Valve surgery, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis surgery, Renal Insufficiency, Chronic surgery
Published: 2024
Full Text: View/download PDF

45. Levosimendan in critical aortic stenosis complicated by cardiogenic shock: Case reports and literature review.

Author: Farina A, Uccello G, Tiberti G, Bianchi A, and Savonitto S
Subjects: Humans, Male, Hydrazones therapeutic use, Pyridazines therapeutic use, Aged, Female, Simendan therapeutic use, Shock, Cardiogenic etiology, Shock, Cardiogenic drug therapy, Aortic Valve Stenosis complications, Aortic Valve Stenosis drug therapy, Cardiotonic Agents therapeutic use
Published: 2024
Full Text: View/download PDF

46. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.

Author: Gentile M, Vigna E, Palmieri S, Galli M, Derudas D, Mina R, Della Pepa R, Zambello R, Martino EA, Bruzzese A, Mangiacavalli S, Zamagni E, Califano C, Musso M, Conticello C, Cerchione C, Mele G, Di Renzo N, Offidani M, Tarantini G, Casaluci GM, Rago A, Ria R, Uccello G, Barilà G, Palumbo G, Pompa A, Vincelli D, Brunori M, Accardi F, Amico V, Amendola A, Fontana R, Bongarzoni V, Rossini B, Cotzia E, Gozzetti A, Rizzi R, Sgherza N, Ferretti E, Bertuglia G, Nappi D, Petrucci MT, Di Raimondo F, Neri A, Morabito F, and Musto P
Subjects: Humans, Antineoplastic Combined Chemotherapy Protocols adverse effects, Dexamethasone therapeutic use, Lenalidomide therapeutic use, Proteasome Inhibitors therapeutic use, Retrospective Studies, Controlled Clinical Trials as Topic, Multiple Myeloma diagnosis, Multiple Myeloma drug therapy, Multiple Myeloma etiology
Abstract: In the ELOQUENT-3 trial, the combination of elotuzumab, pomalidomide and dexamethasone (EloPd) proved to have a superior clinical benefit over pomalidomide and dexamethasone with a manageable toxicity profile, leading to its approval for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. We report here a real-world experience of 200 cases of RRMM treated with EloPd in 35 Italian centers outside of clinical trials. In our dataset, the median number of prior lines of therapy was two, with 51% of cases undergoing autologous stem cell transplant and 73% having been exposed to daratumumab. After a median follow-up of 9 months, 126 patients had stopped EloPd, most of them (88.9%) because of disease progression. The overall response rate was 55.4%, a finding in line with the pivotal trial results. Regarding adverse events, the toxicity profile in our cohort was similar to that in the ELOQUENT-3 trial, with no significant differences between younger (<70 years) and older patients. The median progression-free survival was 7 months, which was shorter than that observed in ELOQUENT-3, probably because of the different clinical characteristics of the two cohorts. Interestingly, International Staging System stage III disease was associated with worse progression-free survival (hazard ratio=2.55). Finally, the median overall survival of our series was shorter than that observed in the ELOQUENT-3 trial (17.5 vs. 29.8 months). In conclusion, our real-world study confirms that EloPd is a safe and possible therapeutic choice for patients with RRMM who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
Published: 2024
Full Text: View/download PDF

47. Myocarditis and Chronic Inflammatory Cardiomyopathy, from Acute Inflammation to Chronic Inflammatory Damage: An Update on Pathophysiology and Diagnosis.

Author: Uccello G, Bonacchi G, Rossi VA, Montrasio G, and Beltrami M
Abstract: Acute myocarditis covers a wide spectrum of clinical presentations, from uncomplicated myocarditis to severe forms complicated by hemodynamic instability and ventricular arrhythmias; however, all these forms are characterized by acute myocardial inflammation. The term "chronic inflammatory cardiomyopathy" describes a persistent/chronic inflammatory condition with a clinical phenotype of dilated and/or hypokinetic cardiomyopathy associated with symptoms of heart failure and increased risk for arrhythmias. A continuum can be identified between these two conditions. The importance of early diagnosis has grown markedly in the contemporary era with various diagnostic tools available. While cardiac magnetic resonance (CMR) is valid for diagnosis and follow-up, endomyocardial biopsy (EMB) should be considered as a first-line diagnostic modality in all unexplained acute cardiomyopathies complicated by hemodynamic instability and ventricular arrhythmias, considering the local expertise. Genetic counseling should be recommended in those cases where a genotype-phenotype association is suspected, as this has significant implications for patients' and their family members' prognoses. Recognition of the pathophysiological pathway and clinical "red flags" and an early diagnosis may help us understand mechanisms of progression, tailor long-term preventive and therapeutic strategies for this complex disease, and ultimately improve clinical outcomes.
Published: 2023
Full Text: View/download PDF

48. Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significance.

Author: Giuffrida G, Markovic U, Condorelli A, Duminuco A, Calafiore V, Conticello C, Romano A, Grasso S, Riccobene C, Ragusa MTV, Esposito B, Nicolosi D, Calagna M, Nardo A, Consoli U, Uccello G, Di Giacomo V, Neri S, Cingari MR, Rodà F, Innao V, Fiumara A, Duro G, Zizzo C, and Di Raimondo F
Subjects: Humans, Aged, Prevalence, Monoclonal Gammopathy of Undetermined Significance complications, Monoclonal Gammopathy of Undetermined Significance diagnosis, Monoclonal Gammopathy of Undetermined Significance epidemiology, Gaucher Disease complications, Gaucher Disease diagnosis, Gaucher Disease epidemiology, Paraproteinemias, Anemia
Abstract: Background: Gaucher disease (GD) is a rare autosomal recessive inherited disorder caused by the lysosomal enzyme acid β-glucosidase deficiency. Many patients experience a critical delay in the diagnosis of up to 8-10 years due to its rarity and variability in signs and symptoms, with the consultation of several specialists., Patients and Methods: This prospective observational study analyzed the prevalence of GD in 600 patients with monoclonal gammopathy of uncertain significance (MGUS) from January 2018 until February 2022., Results: The mean age of participants was 66 years, with a mean monoclonal component of 0.58 g/dL. In 433 MGUS patients with available data, anemia (hemoglobin level < 10 g/dL) was present in 31 patients (7%), and thrombocytopenia (platelet count <100.000/mm 3 ) in 24 (5.5%). Of 600 MGUS patients tested for acid β-glucosidase enzyme activity, 7 patients (1.2%) had activity below 2.5 nmol/h/mL. In comparison, GBA gene analysis was executed in 110 patients. It revealed 4 patients (0.7%) affected by GD (3 patients with compound heterozygous mutation and 1 with homozygous mutation), with a prevalence of 1 every 150 MGUS patients. Furthermore, 12 out of the remaining 106 evaluated patients (11%) were carriers of a single heterozygous mutation while having regular enzyme activity., Conclusions: The clinical heterogeneity of GD and frequent lack of awareness among physicians often lead to diagnostic delays and severe clinical manifestations. The role of MGUS in the presence of at least one clinical sign, such as low platelet count, organomegaly, bone pain, or bleeding tendency, could aid in initiating GD screening with DBS, thus reducing the period between symptom onset and the diagnosis of this rare disease., (© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
Published: 2023
Full Text: View/download PDF

49. Effect of acute CORticosteroids on conduction defects after Transcatheter Aortic Valve Implantation: the CORTAVI study.

Author: Barone L, Muscoli S, Belli M, Di Luozzo M, Sergi D, Marchei M, Prandi FR, Uccello G, Romeo F, and Barillà F
Subjects: Humans, Bundle-Branch Block diagnosis, Retrospective Studies, Prednisone adverse effects, Cardiac Conduction System Disease diagnosis, Cardiac Conduction System Disease complications, Arrhythmias, Cardiac diagnosis, Arrhythmias, Cardiac etiology, Arrhythmias, Cardiac prevention & control, Adrenal Cortex Hormones, Aortic Valve surgery, Treatment Outcome, Transcatheter Aortic Valve Replacement adverse effects, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis surgery, Atrioventricular Block therapy, Pacemaker, Artificial adverse effects
Abstract: Aims: Conduction abnormalities, requiring a permanent pacemaker (PPM), are the most common electrical complications after transcatheter aortic valve implantation (TAVI). The exact mechanism for conduction system defects is not yet clear. The local inflammatory process and edema are thought to play a role in the development of electrical disorders. Corticosteroids are effective anti-inflammatory and antiedematous agents. We aim to investigate the potential protective effect of corticosteroids on conduction defects after TAVI., Methods: This is a retrospective study of a single center. We analyzed 96 patients treated with TAVI. Thirty-two patients received oral prednisone 50 mg for 5 days after the procedure. This population was compared with the control group. All patients were followed up after 2 years., Results: Of the 96 patients included, 32 (34%) were exposed to glucocorticoids after TAVI. No differences in age, preexisting right bundle branch block or left bundle branch block, or valve type were seen among patients exposed to glucocorticoids versus those who were unexposed. We observed no significant differences between the two groups in the overall frequency of new PPM implantations during hospitalization (12% vs. 17%, P = 0.76). The incidence of atrioventricular block (AVB) (STx 9% vs. non-STx 9%, P = 0.89), right bundle branch block (STx 6% vs. non-STx 11%, P = 0.71), and left bundle branch block (STx 34% vs. non-STx 31%, P = 0.9) was not significantly different between the STx and non-STx groups. At 2 years after TAVI, none of the patients had implanted PPM or had severe arrhythmias documented by 24-h Holter ECG or cardiac examination., Conclusion: Oral prednisone treatment does not appear to significantly reduce the incidence of AVB requiring acute PPM implantation after TAVI., (Copyright © 2023 Italian Federation of Cardiology - I.F.C. All rights reserved.)
Published: 2023
Full Text: View/download PDF

50. Usefulness of Coronary Tools for Complex Aortic Valve Crossing During Contrast-Zero TAVR.

Author: Pellicano M, Santangelo G, Briguglia D, Pellegrini D, Uccello G, Montonati C, Polizzi G, Giannini F, Tespili M, and Ielasi A
Subjects: Humans, Aortic Valve diagnostic imaging, Aortic Valve surgery, Treatment Outcome, Risk Factors, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis diagnosis, Aortic Valve Stenosis surgery, Heart Valve Prosthesis
Published: 2023
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

103 results on '"Uccello G"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources